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ABSTRACT OF DISSERTATION 
 
LOOKING TO THE FUTURE OF STROKE TREATMENT: COMBINING 
RECANALIZATION AND NEUROPROTECTION IN ACUTE ISCHEMIC 
STROKE 
 
Stroke is the 5th leading cause of death in the U.S. with 130,000 deaths and 
around 800,000 affected annually. Currently, there is a significant disconnect 
between basic stroke research and clinical stroke therapeutic needs. Few animal 
models of stroke target the large vessels that produce cortical deficits seen in the 
clinical setting. Also, current routes of drug administration, intraperitoneal and 
intravenous, do not mimic the clinical route of intra-arterial drug administration.   
To bridge this divide, we have retro-engineered a mouse model of stroke from 
the current standard of care for emergent large vessel occlusion (ELVO) stroke, 
endovascular thrombectomy, to include selective intra-arterial pharmacotherapy 
administration. Using the tandem transient common carotid and middle cerebral 
artery occlusion (MCAo) model to induce stroke, we threaded micro-angio tubing 
into the external carotid artery (ECA) towards the bifurcation of the common 
carotid and internal carotid arteries (CCA/ICA) allowing for the delivery of agents 
to the site of acute ischemia. Our model was optimized through a flow rate and 
injection volume study using carbon black ink injected through the intra-arterial 
model at different flow rates and injection volumes. The purpose of this study 
was to demonstrate that our injections were arriving at the site of ischemia and to 
improve injection volumes for future dosing while mitigating systemic side effects 
by preventing or minimizing systemic distribution. We determined that a flow rate 
of 2.5 µl/minute and injection volume of 10 µl was optimal. Next, we tested 
potential neuroprotective compounds nitroglycerin, verapamil, and a combination 
of verapamil and lubeluzole. Compounds were chosen for drug synergy and to 
target specific pathways in either an acute or delayed manner. Acute treatments 
included nitroglycerin and/or verapamil while delayed treatment included 
lubeluzole. The known mechanism of action for FDA approved nitroglycerin is 
through vessel dilation that results in increased blood flow to the treated region. 
 
A secondary mechanism of nitroglycerin is the production of nitric oxide, which 
has demonstrated antioxidant and anti-apoptotic effects when processed and 
released from cells surrounding the blood vessels. Verapamil, a calcium channel 
blocker, also FDA-approved for cerebral artery vasospasm: is thought to act by 
blocking the L-type calcium channels on the cell membrane from opening 
following membrane depolarization after insult. Finally, lubeluzole, also FDA-
approved, is proposed to work as an NMDA modulator inhibiting the release of 
glutamate and nitric oxide synthase and blocking sodium and calcium channels. 
Through our stroke model we were able to demonstrate that each drug(s) 
showed a significant decrease in infarct volume and improved functional recovery 
while simultaneously minimizing potential systemic side effects suggesting that 
our stroke model may improve the preclinical validation of potential stroke 
therapies and help bridge the bench to bedside divide in developing new stroke 
therapies.  
 
KEYWORDS: Acute Ischemic Stroke, Intra-arterial, Emergent Large Vessel 
Occlusion, Pharmacotherapy, Neuroprotection 
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Chapter 1: General Introduction 
 
 Ischemic stroke is defined as a disruption of blood flow leading to a loss of 
oxygen and nutrient-rich blood to a region of the brain, which then causes cellular 
damage to brain tissue. This leads to neurological deficits, brain swelling, and 
possibly death. There are two forms of stroke; ischemic, which is caused by a 
clot or thrombus and obstructs blood flow to the brain (responsible for 87% of 
strokes), and hemorrhagic which is caused by a blood vessel wall rupturing and 
leakage of blood into the surrounding tissue (responsible for 13 % of strokes). In 
the United States, ischemic stroke is the 5th leading cause of mortality with 
140,000 affected, but the leading cause of long-term morbidity with 800,000 
affected annually (1, 2). The incidence of stroke is expected to double by 2050, 
and affect a wider range of aged individuals, which is related to an increasing 
aging population and a younger generation becoming sedentary with poor diet 
and activity (3). More people are surviving stroke due to knowledge of early 
warning signs, as well as medical care that is readily available and advanced. 
The most deadly and disabling form of ischemic stroke is emergent large vessel 
occlusion (ELVO). ELVO is characterized when large vessels of the brain such 
as the internal carotid artery (ICA), M1 and M2 segment of the middle cerebral 
artery (MCA), vertebral and basilar artery are occluded (4).    
 ELVO causes a large territory of brain to lose oxygen and nutrients, 
causing apoptosis and death to the neural unit. Apoptosis occurs through two 
pathways, extrinsic or death receptor pathway, and intrinsic or mitochondrial 
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pathway. ELVO induces the intrinsic apoptotic pathway through nutrient loss and 
hypoxia (oxygen deficient environment) which leads to a cellular cascade 
resulting in death. In short, external stimuli signal a change in the inner 
mitochondrial membrane releasing pro-apoptotic proteins into the cytosol, and 
these pro-apoptotic proteins activate the caspase dependent pathway that will 
translocate into the nucleus causing DNA fragmentation, ultimately resulting in 
cellular death (5). By targeting specific receptors, channels or pathways we hope 
to prevent further damage. The damaging mechanisms may proceed through 
rapid nonspecific cell lysis (necrosis) or by active form of cell demise (apoptosis 
or necroptosis), depending upon the severity and duration of the ischemic insult 
(6).  
 There are limited treatments available for ELVO, which consist only of 
supportive care for downstream effects from stroke (brain edema and herniation, 
and systemic secondary issues), and thrombolysis (therapies to re-open the 
vessel and re-establish blood flow). Currently there is only one FDA-approved 
pharmacotherapy, tissue-plasminogen activator (t-PA), whose mechanism of 
action is to help break down a clot by fibrinolysis or the activation of plasmin 
through a series of reactions (7). Due to extensive exclusion criteria such as; a 
4.5 hour therapeutic window, diabetes, older than 85 years of age, prior stroke, 
and use of blood thinners, only about 14 to 38% of patients are eligible (3, 8). 
Recently, a new therapy, endovascular thrombectomy (ET), was introduced and 
successfully completed numerous clinical trials (9-11). Now considered standard 
of care, ET is the mechanical removal of a clot by threading a catheter through 
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the patient’s vasculature to the site of occlusion and removing the clot (9-11). 
Contrary to intravenous (IV) t-PA, ET is available to a larger portion of the 
population due to fewer exclusion criteria and wider applicability. 
 While both ET and IV-tPA have improved patient survival and clinical 
outcome, the overall improvement beyond treatment has not mirrored the 
improved ability to rapidly recanalize an occluded vessel (9, 12, 13). This 
disconnect between successful recanalization using ET and/or IV t-PA and 
improved clinical outcome highlights the need for adjunctive therapies. Currently 
there is no adjunctive therapy, t-PA included, that confers neuroprotective or 
neuroreparative benefits. There have been a number of clinical trials looking at 
potential neuroprotective compounds ranging from glutamate blockers to free 
radical scavengers with all showing little to no benefit (14, 15). Many of these 
compounds showed benefit in the rodent model but failed to translate in a clinical 
setting (14, 16). Likely causes of failure include administration of drug long after 
the therapeutic window (up to 48 hours), as well as drug administration to 
patients whose vessels were still blocked (patients who did not receive 
successful concomitant thrombolysis) (15, 17). Stroke is an acute disease and 
treatments that fail to reach the site of ischemia because the vessel remains 
blocked or the therapeutic window of opportunity has passed are unlikely to 
succeed clinically (15).  
 The aim of this project is to use a clinically relevant mouse model of acute 
ischemic stroke that allows us to guarantee recanalization of the previously 
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occluded vessel while mimicking the clinical ability to selectively administer a 
potential neuroprotective agent directly to the site of ischemia. There are 
numerous mouse models of stroke available; small vessel occlusions include the 
photothrombotic and embolic models. Large vessel occlusions like ELVO include 
the suture (suture threaded through vasculature to occlude the Circle of Willis), 
chemical induction (direct application to the targeted vessel), and filament 
(ipsilateral tandem occlusion of the common carotid and middle cerebral 
arteries). Below we will briefly describe each, and discuss the reasons for the 
model design. 
Mouse Models of Stroke - Optimizing a Model 
Small Vessel Occlusion 
Photothrombotic Model  
 The photothrombotic model mimics small vessel occlusions in the vessels 
of the cortex distal to the large vessels of the Circle of Willis, and distal cortical 
branches. The photothrombotic model allows researchers to induce an ischemic 
event targeting specific motor or sensory functions in the specific areas of the 
cortex by occluding vessels supplying the targeted function (18-20). An infarct is 
induced following the injection of a dye, Rose Bengal, that is then activated using 
a laser or other light source to cause the dye to coagulate and block the intended 
vessel on the cortical surface (21). Dye activation and occlusion of the vessel can 
be achieved in most parts of the cerebrovasculature and is not confined to the 
motor or sensory cortex but most studies look at deficits from these regions. As 
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such, the preclinical model correlates to a small vessel infarct in a confined 
cortical brain region.  
 Stroke studies using the photothrombotic model have shown it to be 
representative of a small vessel occlusion by comparing functional and sensory 
deficits, using an animal model (rat and mouse). Upon dye injection and 
activation targeting the motor and sensory cortex (middle cerebral artery) a 
functional and sensory deficit is seen within a few hours affecting the 
contralateral forelimb and hind limb. Tests used to assess functional deficits are 
the wire hang, cylinder test, grid walk, reaching, and pole test; while deficits in 
sensory function use the adhesive removal test (18-20).  
 Infarct volume measurements for the photothrombotic model show a core 
and penumbral region around the infarct/laser-dye activated, and infarct volume 
measurements range from 1 - 2 mm3 to 8 - 10mm3 depending on the 
aforementioned parameters (18, 20). Cellular differences, such as astrocytes and 
microglial infiltration and decreased neuronal survival, appear in the stroked 
animals compared to controls (18, 20).  
 Advantages of the photothrombotic model are minimal surgical impact on 
the animal for stroke induction, graded lesion volume, ability to target a specific 
region for motor, sensory or sensorimotor deficit, and high reproducibility coupled 
with long-term survival. Disadvantages of the model are microvascular insult, 
small penumbra,  permanent occlusion, occlusion and evolution of infarct occurs 
rapidly, small infarct volume when compared to other stroke models, decreased 
motor or sensory deficit, adverse effects to blood vessel walls potentially leading 
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to breakdown and edema in the parenchyma (22). This model is optimal for 
mimicking small vessel occlusion, particularly the more distal region of the MCA, 
which present with facial, arm, and leg weakness or inability to move.  
Embolic Model 
  The embolic clot model, another small vessel occlusion model, best 
mimics the human condition to achieve a clinically relevant thrombus induced 
infarct. The embolic clot model uses a clot derived from coagulated blood of the 
animal, and is injected through the ICA into the MCA. The clot circulates into the 
vasculature of the cortex until it becomes lodged in a cortical vessel where it will 
obstruct blood flow to a particular region causing an infarction (deficits are 
representative of where the clot occludes and can have some variability) (23). 
Briefly describing the procedure, blood from the animal (collected prior to clot 
injection) is allowed to coagulate into a clot, the clot is loaded into a micro-tubing 
attached to a micro-syringe and injected into the cervical or cephalic vasculature 
depending on animal’s (rat or mouse) size (24).  
 The embolic model is considered variable by many due to its non-specific 
infarct size and placement. This is in direct contrast to mechanical models which 
allow direct placement of a stroke either in the cortex, subcortical areas or both. 
While the benefit of the embolic model is to mimic the heterogeneity of 
thromboembolic stroke in humans, that same heterogeneity is problematic when 
using in vivo preclinical models to study stroke, where the goal is to control the 
infarct from one animal subject to the next. Because of aforementioned 
variabilities, the embolic clot model can present with functional, cognitive or a 
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combination of both deficits depending on clot placement and duration. 
Successful clot delivery can be tested using a variety of functional and cognitive 
tests; functional deficits can be tested using the beam walk, adhesive removal, 
and corner test (25, 26). Cognitive deficits are best measured using the radial 
arm water maze, and various versions of neurological scores (27-29). Functional 
or cognitive testing using this model will show differences between stroked and 
control groups within 5 hours of infarct induction and can persist up to 7 days.  
 Degree of infarct volume is variable in this model due to varying clot size, 
location of occlusion, and duration, but does present with a core and penumbral 
region. Infarct volume measurements range from 3-56 mm3 depending on 
aforementioned parameters (30, 31). Inspection of the infarcted region shows 
astrocytic and microglial infiltration in the core and penumbral region within hours 
of stroke leading to scar formation over 21 days. 
 Widely considered the most clinically relevant model, the embolic model 
requires surgery to inject the clot causing manipulation and permanent occlusion 
of cervical vasculature to ensure clot delivery via the ICA to MCA. Advantages of 
this model are both functional and cognitive deficits, true to the clinical condition, 
and variable infarct volume representing the population of patients. Most 
importantly, it can be a very relevant model for testing systemic administration of 
t-PA and other thrombolytics (32, 33). Disadvantages of the model include the 
need for extensive surgical manipulation, the likelihood of permanent occlusion 
by the thrombus, and aforementioned variability.  
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Large Vessel Occlusion Models 
Suture Model - MCAO 
 Large vessel occlusion is produced using mechanical stroke induction and 
provides a cortical and/or subcortical infarct that manifests in both functional and 
cognitive deficits through the occlusion of the ICA and MCA. Functional and 
cognitive deficits require occlusion of the proximal segments (M1/M2) of the MCA 
with particular attention to the lenticulostriate and anterior cerebral arteries (ACA) 
of the Circle of Willis. Mechanical induction is achieved through the MCAO model 
by threading a predetermined length of suture (2-0 or 4-0) with a heat induced 
rounded end (decreases inflammatory vessel wall response) - through the 
external carotid artery (ECA) into the ICA at the bifurcation of the common 
carotid artery (CCA). The suture is threaded through the ICA towards the Circle 
of Willis and MCA stopping at the transition from ICA to MCA/Circle of Willis. It is 
important to not thread the occlusion suture beyond the distal most portion of the 
ICA for risk of puncturing the MCA and causing cerebral bleeding. Indeed, this 
same model (when used with a non-blunted suture) is used to induce 
intracerebral hemorrhage for study in preclinical models. Occlusion times of the 
ICA/MCA/Circle of Willis are variable but 60 - 90 minutes is common in the 
literature to produce measurable functional and cognitive deficits (34).  
 The MCAO model is a reliable and reproducible model of stroke causing 
large cortical and subcortical infarcts spanning the entire occluded hemisphere. 
Infarct is induced mechanically but does not represent the clinical manifestation 
of a clot and treatment through intravenous (IV)-tPA or ET but rather restores 
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blood flow through suture removal from the ICA. Advantages of the MCAO model 
are its clear functional and cognitive deficits through occlusion of vessels 
providing blood to both cortical (motor/sensory cortex) but also subcortical 
(hippocampal/white matter) areas. Infarct volume, cellular inflammatory infiltration 
and deficits are measurable within days and continue days and weeks post 
stroke allowing for a variety of tests. Functional deficits are measured using the 
vertical pole, hanging wire, open field, and corner test. While cognitive deficits 
can be measured using the Morris or radial arm water maze and novel object 
recognition (34, 35). Disadvantages of the model are its variability in infarct size, 
high mortality rate, significant impact on cerebral edema on post-stroke 
inflammation and outcome, and artificial stroke induction through the 
manipulation of the CCA/ICA and ECA with permanent occlusion of the ECA. 
Endothelin-1 
 The endothelin-1 model is a vasoconstrictor that can be applied targeting 
either arterial or venous supply through surface application or intra-cerebral 
injection. The model is dose dependent and is used to target ischemia in either 
cortical or subcortical regions. Advantages of the model are minimal tissue 
edema, localized ischemic infarct, and specific receptor targeting for interruption 
of astrocyte and neuronal repair. Disadvantages of the model are its lack of 
clinical correlation, failure to target large vessels in an acute manner and 
repeated interference with neural repair (22).  
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Filament Model - MCAo 
 The tandem transient common carotid/middle cerebral artery occlusion 
model (MCAo) of large vessel occlusion is similar to the previously described 
MCAO. It is a mechanical induction of stroke for the cortical region achievable 
through occlusion of the M1/M2 of the MCA. To achieve an infarct in the cortical 
region, affecting primary motor function of the forelimb, requires occlusion of the 
MCA and CCA. A tandem occlusion of the ipsilateral vessels decreases blood 
flow to the cortical region in question ensuring infarct induction. Mechanical 
stroke induction begins with exposing the MCA through a burr hole in the skull 
and using a small wire that is inserted underneath the MCA kinking the vessel 
closed and then a clamp is placed on the CCA to occlude blood flow. Occlusion 
times vary between labs but 60 - 90 minutes is common in the literature (20, 36, 
37). Reperfusion is achievable with removal of the wire filament and clamp, 
however this model can also be used as a permanent model. The MCAo model 
produces a clinically relevant infarct in the cortical region of the MCA and 
surrounding areas (20, 37-40). It mimics a distal M1/M2 MCA occlusion.  
 The MCAo model of stroke induction is reliable and reproducible, which 
yields specific focused infarcts in the cortical region through MCA occlusion. 
While mechanical induction of stroke provides clinically relevant infarcts of the 
cortex, it does not mimic the treatment (IV-tPA or ET) but rather restores blood 
flow through the removal of the MCA filament and CCA clamp. The advantages 
of the MCAo model are infarct volume, cellular response, and functional 
manifestations that present within hours of stroke induction and can be measured 
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days and weeks following. Infarct volume for the MCAo model achieves max 
volume around 3 days with measurable inflammatory cellular infiltration 
(astrocyte and microglia) (38). Functional deficits of the forelimb are seen within 
one day and can be measured using a variety of motor tasks: rotor rod, grip 
strength, wire hang, open field, beam walk, reaching task, tape removal, and 
cylinder test (20, 37). The MCAo model is not well studied or defined for cognitive 
deficit as only the MCA supplying the cortical motor/sensory region is typically 
affected, but a higher than normal branching of the lenticulostriate arteries can 
produce memory deficits. This is not typical and should be taken into account 
when choosing a deficit model of motor, memory, or both following stroke.  
 The advantages of the MCAo model are a reliable, reproducible, low 
mortality, clinically relevant infarct in the MCA region affecting motor function with 
hallmark cellular characteristics and variable occlusion times. Disadvantages of 
the model are its lack of clinically relevant induction (clot) and treatment (IV-tPA 
and/or ET), as well as initial difficulty in mastering the surgical technique. Overall, 
the model provides a number of hallmark measurable characteristics following 
stroke induction and potential treatments. The MCAo provides the best mouse 
model of stroke available to mimic the clinical condition of ELVO, with the 
removal of the clamps as a preclinical correlate to recanalization by 
thrombectomy, with guaranteed recanalization, similar infarct size and location, 
and presentation of physical deficits.  
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Neuroprotective Drug Administration Approach 
Intra-arterial model 
 Our aim was to develop a drug administration model that mimicked 
selective delivery directly to the site of ischemia while already using the exposed 
vasculature of the MCAo model. Developing an intra-arterial (IA) model of 
pharmacotherapy administration allows us to bypass a number of issues that 
plague the systemic administration. By delivering our drug of choice directly to 
the site of ischemia, we are able to guarantee the drug reaches its target site, 
decrease the amount of drug needed, and mitigate any systemic side-effects that 
may occur (38, 39). An IA model could mimic the opportunity seen in the clinical 
condition during thrombectomy since after recanalization of the vessel it is 
possible to selectively deliver targeted drug therapy before completing the 
procedure, guaranteeing the drug reaches the ischemic region.  
 By combining the MCAo and IA model, we have developed a clinically 
relevant mouse model of stroke induction and targeted pharmacotherapy 
administration. Next, we optimized our model to ensure that our drug of choice 
reached the site of occlusion following successful recanalization with little to no 
systemic distribution, and did not produce any systemic side-effects. After 
optimizing our model we selected three FDA-approved drugs previously tested in 
both a pre-clinical and clinical setting: nitroglycerin (also known as glyceryl 
trinitrate, GTN), verapamil, and lubeluzole.  
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Intra-arterial Nitroglycerin 
 Nitroglycerin (GTN) is FDA-approved and used as a vasodilator to open 
collapsed blood vessels in an acute fashion. GTN is commonly used for angina 
pectoris to vasodilate the vessels of the heart following an ischemic event. It 
works by relaxing the smooth muscles surrounding the blood vessel, but also by 
producing nitric oxide (NOx) which works by blocking apoptotic signaling 
cascades. GTN has a short half-life (2 – 7 minutes) and possesses a dual 
mechanism of action, working both acutely (vessel dilation) and delayed (anti-
apoptotic) by the conversion of GTN to NOx (41-43).  
Intra-arterial Verapamil 
 Verapamil, an L-type calcium channel blocker, is FDA-approved and 
currently used to treat cerebral artery vasospasms following successful 
recanalization after ELVO. Administered acutely following membrane 
depolarization, verapamil works by blocking the influx of calcium intracellularly. 
Verapamil is a one pass drug, meaning it will be degraded once it passes 
through the liver and loses it bioactivity and effect if not administered upstream of 
its target site. IA delivery of verapamil ensures it will reach the stroked tissue, 
have its effect on calcium influx and then be degraded by the liver in venous 
return from the brain. This is key, because if verapamil is not degraded in the 
liver and is still bioactive when it reaches the heart it can cause a decreased 
heart rate and increased vessel dilation (44-46).  
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Intra-arterial Lubeluzole 
 Lubeluzole, also FDA-approved, has a less defined mechanism of action 
but is widely accepted as a NMDA modulator blocking glutamate release. 
Lubeluzole demonstrated positive effects in a pre-clinical setting but did not 
translate into the clinical setting and was discontinued due to failure of efficacy 
(47-50). Pre-clinical testing with lubeluzole (0.63 and 1.25 mg/kg) demonstrated 
both a decreased infarct volume and improved functional behavior when 
administered IV within six hours post-infarct (49). Clinically, lubeluzole was 
administered IV initially (7.5mg) and followed with daily IV doses of 10mg for five 
days. Two independent clinical trials produced different results, the first showed 
lubeluzole to be safe and have an improved clinical outcome (51). A second 
study, showed no differences between groups and demonstrated adverse events 
(fever, constipation, and headache) (52). Lubeluzole will be administered in an 
acute fashion with a one-time dose. By delivering the drug selectively to the 
ischemic region we are bypassing systemic circulation and any potential side 
effects.   
Intra-arterial combinational therapy 
 By combining an acute drug with a delayed drug we are targeting specific 
damage that cells are undergoing in the ischemic brain region. Furthermore, as 
cells within the core (closest to the occluded vessel) are in a different stage of 
apoptosis than those cells in the penumbra (radiating away from core), a 
combinational pharmacotherapy approach will allow for a broader range of 
cells/pathways to be targeted, especially if the drugs work in an acute and 
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delayed fashion without overlapping mechanisms of action. With this in mind, 
while both verapamil and GTN are acute drugs, their similar primary mechanism 
of action (vasodilation) prohibits them from being combined due to potential 
blood leakage into the parenchyma due to blood brain barrier break down. 
However, verapamil and lubeluzole working in an acute and delayed setting will 
target different apoptotic pathways, therefore giving a greater chance of blocking 
multiple targeted pathways for potential synergistic effect.  
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Chapter Two: Intra-arterial Model 
Maniskas M, Bix G, Fraser J. Selective intra-arterial drug administration in a 
model of large vessel ischemia. J Neurosci Methods. 2014 Nov 8;240C:22-7. 
PubMed PMID: 25445249. 
 
Introduction 
 Emergent large vessel occlusion (ELVO) affects the vital arteries (ICA, 
MCA, ACA, vertebral and basilar) of the brain. Current therapeutic options for 
ELVO include IV-tPA and/or endovascular thrombectomy (ET). Intra-arterial ET, 
involves the mechanical removal of a clot using a retrieval device threaded 
through the patient’s vasculature (10, 53). From 2004 to 2008, the use of IA 
thrombectomy increased six-fold (54). While advances in medicine such as IV t-
PA and mechanical thrombolysis have shown improved restoration of blood 
perfusion to ischemic brain regions, it has not correlated to improved clinical 
outcomes in patients (12, 53, 55). To date, there are no therapies, including 
thrombolysis, that provides either neuroreparative or neuroprotective benefits 
when administered following successful recanalization of a previously occluded 
vessel. Due to this disparity, the ability to successfully treat stroke patients and 
achieve full recovery remains out of reach.  
 Endovascular thrombectomy begins with a catheter being feed within the 
femoral artery of the leg superiorly until it reaches the aorta in the abdomen and 
thorax. Passing through the aorta of the thorax the catheter will feed further 
superior into the CCA of the neck and into the ICA and MCA of the head. While 
   
 
17 
 
the end goal of ET is to successfully guide the catheter to the clot and remove, 
restoring blood flow, it also provides an opportunity to selectively deliver a 
potential therapeutic compound that has neuroprotective or neuroreparative 
benefits. Delivery of targeted stroke treatments guaranteed to reach the site of 
ischemia provides a number of advantages over systemic administration. These 
advantages include decreased risk of systemic side-effects (increased intra-
cranial pressure, increased heart rate, decreased blood pressure), need for lower 
concentration of therapeutic compound, and increasing the concentration of the 
compound to better reach the ischemic brain region.  
 Years of research and clinical trials has yet to produce a viable compound 
that can be administered as a neuroprotective treatment following acute ischemic 
stroke. A bench-to-bedside approach utilizes the knowledge of researcher and 
clinician to develop new approaches for treating acute ischemic stroke. Modeling 
ET for selective pharmacotherapy delivery, we retro-engineered a mouse model 
to mirror the clinical condition of IA thrombectomy following successful 
recanalization. This allows us to selectively deliver IA pharmacotherapy directly 
to the site of ischemia while also ensuring restoration of blood flow. 
 Attempting to remain as clinically relevant as possible, we modeled our IA 
process as follows: MCAo is induced for 60 minutes, using the already exposed 
vasculature of the neck we advance a catheter from the ECA into the bifurcation 
of the CCA and into the ICA, following 60 minute stroke induction we recanalize 
and inject IA therapeutics without the need for permanent indwelling micro-ports 
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or catheters. Similar to the clinical condition, we are able to successfully 
recanalize, restoring blood flow while also delivering targeted stroke therapeutics. 
While other models of IA exist, they leave long-term microports (surgically 
implanted pump for pharmacotherapy delivery) and indwelling catheters which 
are not clinically relevant for acute ischemic stroke treatment (56, 57). This novel 
approach allows us to administer IA neuroprotective agents in a clinically relevant 
fashion with the minimal amount of surgery.  
 To validate our mouse model of pharmacotherapy administration, it was 
also essential to show that our model could be effectively utilized to deliver 
compounds directly and specifically to the site of ischemia. We found that the 
efficacy of selective delivery of potential pharmacotherapies was dependent upon 
optimized flow rate and injection volume. The study of flow rate and injection 
volume through carbon black ink injection allowed us to demonstrate that a 
compound administered in such a fashion could reach the affected area and its 
injection rate and volume could be optimized for our model. Through this retro-
engineered mouse model, flow rate, and injection volume study we have 
described a method that can be used to test the hypothesis that local delivery of 
pharmacologic agents following ischemic stroke will show improved 
neuroprotection and functional outcomes compared to systemic delivery of 
therapeutic agents.  
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Material and Methods 
Suture, metal wire, micro-angio tubing and syringe preparation 
 Two different sized sutures were used: one 2-0 nylon monofilament suture 
cut two centimeters (cm) in length for occlusion of the CCA and three 6-0 nylon 
braided silk sutures cut 1.0 cm in length for permanent occlusion of the ECA and 
securing of the micro-angio tubing. Metal wire (Small Parts, Logansport, IN) 
0.0127 cm in diameter were cut to a length of 0.1 - 0.15 cm. Using micro forceps 
under a dissecting microscope, a 34 gauge needle (Hamilton Syringe Co., Reno, 
NV) was fitted with a 10 cm length of micro-angio tubing (MRE 010-Braintree 
Scientific, Braintree, MA), the combined needle and tubing were then attached to 
a 100 µl Hamilton Gas Tight syringe (Figure 2.1). 
Animal preparation for surgery 
 The Institutional Animal Care and Use Committee (IACUC) of the 
University of Kentucky approved all procedures, which were conducted in 
accordance with the principles of animal care and experimentation in the Guide 
for the Care and Use of Laboratory Animals. Three month old C57/Bl6 male 
(Jackson Laboratory) mice were anesthetized via intraperitoneal injection with a 
combination Ketamine/Xylazine mixture in a saline solution using a weight based 
dosing scale. The mice were shaved on the left temporal region of the head from 
the lateral corner of the left eye to the medial region of the left ear with the 
resultant shaved region being 0.75 cm by 0.75 cm (Figure 2.2A). The shaved  
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INTRA-ARTERIAL SYRINGE, NEEDLE, AND TUBING CONSTRUCTION  
Figure 2.1. Image of 100µl Hamilton Gas Tight syringe with 34 gauge needle 
and micro-angio tubing attached.  
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SURGICAL INCISION SITES FOR STROKE SURGERY 
 
Figure 2.2. A. Mouse in supine position with box outlining shaved thoracic 
region, a midline incision is made from apex of ribcage to angle of the mandible., 
B. Mouse in pronated position with box outlining shaved temporal region, 
temporal incision from lateral corner of left eye to medial region of left ear.  
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area of the cervical and thoracic region started at the angle of the mandible and 
extended to the apex of the ribcage with a width spanning from forelimb axillary 
region to the opposite forelimb axillary region (Figure 2.2B). The shaved areas 
were cleaned three times with alcohol prep pads followed by a cotton tipped 
applicator moistened with Betadine. 
Surgical Preparation 
 Once the mouse was fully anesthetized it was placed on a heated (to 
control body temperature) elevated platform. With the mouse in the supine 
position, the head was secured using teeth restraints and the forelimbs and tail 
were secured to the platform using surgical tape (Figure 2.2A & 2.2B). 
MCAo stroke surgery 
 To induce focal cerebral ischemia, we used the previously described 
transient tandem ipsilateral CCA/MCA occlusion stroke model (MCAo) (37, 40). 
With the mouse in the supine position a midline incision was made allowing us to 
isolate and elevate the CCA to place a 2-0 suture underneath. It is important to 
note that the vagus nerve runs parallel to the CCA and should be separated so 
that it is not clamped with the CCA. We then released the surgical tape and 
rotated the mouse so that it was in a pronated position and re-secured. A second 
incision was made in the left temporal region from the lateral corner of the left 
eye to the medial region of the left ear exposing the temporal region. The 
temporalis muscle was reflected, the MCA verified and a small burr hole drilled to 
allow the metal wire to be placed under the MCA. The mouse was repositioned to 
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the supine position for temporary clamping of the CCA, (the occlusion time of the 
CCA/MCA can be varied; our lab occludes for 60 minutes). Before the head was 
sutured, blood flow measurements using the Laser Doppler and Speckle were 
taken using the process detailed in the following section. All surgical sites were 
temporarily sutured with 4-0 pre-needled nylon suture.  
Laser Doppler and Laser Speckle for blood flow measurement 
 To measure blood flow in the ipsilateral MCA, a Perimed Laser Doppler 
flow meter (Periflux System 5000, Perimed) probe was placed directly over the 
MCA touching the skull, a reading was taken pre-occlusion (before MCAo) and 
the probe was placed in the same spot to take the post-occlusion measurements 
after insertion of the metal wire under the MCA and clamping of the CCA to 
confirm decreased blood flow. The ipsilateral hemisphere total blood flow was 
measured using a Laser Speckle (Pericam PSI HR, Perimed) which was 
positioned 15 cm above the exposed skull of the mouse. The laser sighting 
system was employed to ensure consistent measurements, a permanent marker 
was used to make a landmark dot along the sagittal suture to ensure centering of 
the sighting system to confirm pre and post-occlusion measurements were 
consistent. Post-occlusion measurements were taken at 5, 10 and 15 minutes 
post occlusion.  
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Placement of micro-angio tubing into the ECA 
ECA suture placement 
 With the anesthetized mouse in the supine position the temporary sutures 
were removed and the previously isolated CCA was exposed, moving superiorly 
along the CCA (lateral to the trachea) to the bifurcation of the ECA and ICA. With 
the bifurcation located, it is necessary to further expose the ECA and ICA by 0.50 
- 0.75 cm using angled or straight fine tipped micro forceps for suture placement 
and clamp insertion (Figure 2.3A). Using a pair of fine tipped curved forceps, the 
ECA was gently lifted allowing three 1.0 cm lengths of 6-0 suture to be threaded 
underneath, and the sutures were transferred to fine tipped curved forceps from 
a pair of fine straight tipped forceps. The sutures were then separated so that the 
first suture was placed at the bifurcation of the CCA, the second suture was 
placed midway between the bifurcation and the superior most exposed portion of 
the ECA, and the third suture was placed at the superior most exposed area of 
the ECA near the muscle (Posterior Belly of the Digastric-PBD) (Figure 2.3B). 
Once all the sutures were placed, the superior most suture was tied to 
permanently occlude the ECA. The superior thyroid artery should be identified, if 
it arises proximal to the distal permanent ECA suture, then a fourth suture should 
be threaded underneath to achieve permanent occlusion.  
Nicking the ECA and micro-angio tubing placement 
 With the ECA (and superior thyroid) artery permanently occluded, a 
curved removable clamp (Micro Serrefines-Fine Science, Foster City, CA) was  
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INTRA-ARTERIAL SUTURE AND TUBING PLACEMENT 
Figure 2.3. A. Outline of CCA/ECA/ICA with trachea and 
sternocleidomastoid (SCM) as landmarks., B. Sutures 1, 2 and 3 
placement and white line marking CCA bifurcation, region framed by 
trachea, sternocleidomastoid (SCM), and posterior belly of the digastric 
(PBD)., C. Micro-angio tubing inserted into ECA towards CCA bifurcation 
and secured with suture 2., D. ECA suture ligated. 
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attached to the ICA forming a closed system between the clamped CCA, the 
suture ligated ECA and the clamped ICA. The ECA was then nicked just above 
the second suture with a pair of micro-scissors (Vannas Spring Scissors-Fine 
Science, Foster City, CA) to allow for the micro-angio tubing (MRE010 Braintree, 
Braintree, MA) attached to the Hamilton Syringe to be inserted using a pair of 
angled forceps (for easier tubing insertion it is recommended to cut the tip of the 
inserted tubing at a 45° angle) (Figure 2.3C). A pair of angled micro forceps were 
used to grasp the tubing 0.5 cm from the tip and a pair of curved forceps to grasp 
the tied suture of the ECA, which helped prevent the ECA from rolling and gave 
better stability for tubing insertion. Once the tubing was inserted and the tip 
placed at the bifurcation of the CCA, the second suture was tied securing the 
tubing and forming a tight seal between the tubing and ECA vessel wall (Figure 
3D). Removal of the clamped ICA occurred after ensuring a tight seal around the 
suture tubing. Given the small blood volume of a mouse, care must be taken to 
minimize blood loss during these steps, as a significant blood loss can alter 
stroke volume and study outcomes.  
CCA clamp and MCA metal wire removal  
 At the end of the predetermined occlusion time, the CCA clamp and the 
metal wire were removed with the mouse in the supine position to restore blood 
flow to the previously occluded area. To better visualize and remove the 
temporary sutures and MCA metal wire, the tape securing the left forelimb was 
removed and the body angled to the contralateral side.  
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Carbon black ink flow rate and injection volume 
 After a five minute waiting period for reperfusion, the 100 µl Hamilton 
syringe with a 34 gauge needle and micro-angio tubing was loaded with a 
mixture of fountain inks (Pelikan-Fount India & Higgins Fountain Pen India) in a 
1:9 ratio (58). The syringe was attached to a syringe pump (BS-8000, Braintree 
Scientific, Braintree, MA) with flow rate settings of 1 µl, 2.5 µl, 5 µl and 10 µl per 
minute at volumes of 10 µl, 25 µl, 50 µl and 100 µl for each flow rate. 
Removal of micro-angio tubing and permanent ECA occlusion  
 To remove the micro-angio tubing, the suture on the proximal ECA was 
first secured at the bifurcation of the CCA ensuring that the ECA was 
permanently occluded for the remainder of the experiment. With the first suture 
tied, the tubing was gently removed from the vessel with a pair of fine tipped 
forceps holding the second suture acting as an anchor to better assist in tubing 
removal. When the tubing was fully removed from the ECA, the suture was 
rechecked to ensure no blood leakage and the incision in the neck and head 
were permanently closed using pre-needled 4-0 nylon monofilament suture.  
Reperfusion 
 Reperfusion of the MCA was confirmed using the Laser Doppler flow 
meter at 15 minutes post occlusion and Laser Speckle imaging at five minute 
intervals starting at reperfusion to 15 minutes post occlusion.  
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Animal Recovery 
 The mouse was allowed to recover in a heated recovery cage to regulate 
body temperature until it met or exceeded the guidelines set forth in our 
approved IUCAC protocol. Once the mouse was fully recovered it was returned 
to its home cage with its littermates in standard laboratory housing in the 
University Of Kentucky Division Of Laboratory Animal Resources.  
Stroke Volume Assessment 
Euthanasia 
 On post stroke day three or seven, mice were euthanized via cervical 
dislocation and decapitated for removal of brain (37).  
Removal of brain 
 A midline incision was made using a pair of blunted scissors on the scalp 
of the decapitated head exposing the calvarium. Next a pair of fine tipped 
scissors were inserted at the base of the skull and used to cut the calvarium and 
thereby expose the brain. The brain was lifted from the skull base using a pair of 
blunted curved forceps and placed in a 1X PBS solution for a quick 10 - 15 
second wash.  
Brain slicing and staining 
 The removed brain was transferred to a brain mold and sliced into 2 
millimeter (mm) thick sections with a surgical blade. The brain sections were then 
transferred to a petri dish and stained using a 1% solution of 2,3,5-
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triphenyltetrazolium chloride (TTC) for 10 minutes to visualize ischemic infarct 
(37).  
Infarct measurement 
 TTC stained brain sections were placed horizontally from frontal to 
occipital in a 3.0 cm wide petri dish and were scanned using a HP Scanjet 
G4050. The scanned images were input into NIH Image J for infarct analysis 
(37). Images were analyzed based on pixel density per mm2. Briefly, a ruler was 
scanned along with brain sections to determine pixel per millimeter squared. With 
the known pixel per millimeter squared, scanned TTC brain sections were 
measured using NIH Image J, measured sections were infarct, ipsilateral and 
contralateral hemispheres. Infarct volume measurements were assessed using 
the formula: Infarct area = Infarct – (Contralateral hemisphere/Ipsilateral 
hemisphere), this formula accounts for edema in both contralateral and ipsilateral 
hemispheres.  
Results 
Surgical outcome 
 The animals tolerated the procedure well with surgical effects (lethargy, 
decreased grooming, and eating) subsiding and resumption of normal behavior 
and eating habits within 24 hours. There was a decrease in body weight over two 
days averaging 2 - 3 grams (if stroke is carried out to post stroke day 7, weight is 
regained). The MCAo and IA injection models have a low mortality rate of less 
than 5% with death being attributed to ruptured MCA or CCA. Exclusions from 
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the IA study occurred when the clamp perforated the CCA upon clamp removal 
or when the metal wire pierced the MCA as it was being inserted or removed 
from underneath the MCA. These animals were excluded based on failure to 
guarantee recanalization and targeted drug delivery. 
Laser Speckle and Laser Doppler 
 Laser Speckle imaging (n = 7) showed a significant (P < 0.017) 25.26% 
decrease in hemisphere blood flow from baseline to occlusion and an increase of 
5.23% from occlusion to 15 minutes reperfusion (Figure 2.4A). Laser Doppler (n 
= 22) showed a significant (P < 0.001) 83.81% decrease in MCA flow from 
baseline to occlusion and an increase of 59.15% from occlusion to 15 minute 
reperfusion when compared to baseline (Figure 2.4B). 
Infarct Volume 
 Using NIH Image J software, the sectioned and stained brains had an 
average infarct measurement of 19.89 mm3, which was significantly (P < 0.001) 
increased when compared to sham measurements (n = 10 and 8, respectively, 
Figure 4C).  
Flow Rate and Injection Volume 
 Flow rate and injection volume studies (n = 3) were performed to optimize 
selectivity of infusion to the ipsilateral hemispheric cerebral circulation (Table 1). 
Injection volumes were 100 microliter (µl), 50 µl, 25 µl and 10 µl with flow rates of 
1.0 µl, 2.5 µl, 5 µl, 7.5 µl and 10 µl/minute. The 100µl volume showed  
 
 
 
 
3
1
 
 
  
 
Figure 2.4. A. Laser Speckle (n = 7): Blood flow measurements of the ipsilateral hemisphere at time 
points Baseline (before occlusion), Post Occlusion (immediately after occlusion), 10 minutes 
reperfusion (Rp) and 15 minutes Rp. ** indicates P = 0.017., B. Laser Doppler (n = 22) MCA blood flow 
measurements at time points Baseline (before occlusion), Occlusion (immediately after occlusion) and 
Reperfusion (5 minutes reperfusion). *** indicates P < 0.001., C. Infarct volume measurements vehicle 
(n = 10) versus sham (n = 8) after MCAo surgery PSD 3. *** indicates P < 0.001. 
C A B 
STROKE PERFUSION AND INFARCT VOLUME MEASUREMENTS 
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INTRA-ARTERIAL FLOW RATE AND INJECTION VOLUME DESIGN 
   
Table 1. Injection Rates at 10, 7.5, 5.0, 2.5 and 1.0 μl/min at Injection Volumes 
100, 50, 25 and 10 μl. Ipsilateral and Contralateral staining of the Middle Cerebral 
Artery (MCA) at specific injection rates and volumes, no staining at the 1.0 μl/min 
injection rate due to opposing pressure from the CCA. No further testing of 
injection rate 1.0 μl/min due to inability to overcome opposing pressure. Little to 
no contralateral staining was seen at the injection rate 2.5 μl/min at volumes 10 
and 25 μl. Slight staining (*) was seen in the frontal region of both hemispheres 
due to mice having an azygous Anterior Cerebral Artery. Carbon black ink was 
found throughout the liver and vasculature at injection rates 10, 7.5 and 5.0 μl/min 
and injection volumes 100 and 50 μl with slight staining at 25 μl and no staining 
at 10 μl. 
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contralateral staining at all flow rates except 1 µl/min flow rate which did not 
provide enough force to overcome the opposing blood pressure of the CCA to 
begin ink injection immediately. This flow rate was excluded from further testing. 
The 50 µl volume showed contralateral staining for the 5, 7.5 and 10 µl/min 
infusion rates but little contralateral staining at 2.5 µl/min. The 25 µl volume 
showed contralateral staining for the 5.0, 7.5 and 10 µl/min flow rates but little to 
no contralateral staining at 2.5 µl/min. The 10 µl volume at flow rate 2.5 µl/min 
showed no contralateral staining, leading us to determine the optimal flow rate as 
2.5 µl/min at a volume between 10 and 25 µl. Cross sectional liver images of flow 
rate 2.5 µl/min at volumes listed above show carbon black ink in the 25 and 50µl 
but not in the 10µl (Figure 2.5 A - K). It is of note that with a different gauge 
needle and micro-angio tubing the opposing blood pressure of the CCA could be 
overcome by varying the above measurements (14, 16). 
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INTRA-ARTERIAL CARBON BLACK STAINING OF CORTEX, CIRCLE OF 
WILLIS, AND LIVER  
  
 
I J K 
Figure 2.5. Red arrows signify carbon black ink staining in cerebral and 
liver vasculature., A – D. Dorsal view of brain at injection rate 2.5 µl/min 
at volume 10 µl, 25 µl, 50 µl and 100 µl., E – H. Circle of Willis at injection 
rate 2.5 µl/min at volumes 10 µl, 25 µl, 50 µl and 100 µl., Cross section 
of liver at injection rate 2.5 µl/min at volume 10 µl, 25 µl, and 50 µl.  
10 µl 25 µl 100 µl 50 µl 
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Discussion 
 The advancement of neuroprotective pharmacotherapy for ischemic stroke 
has been complicated by failures in translation from the laboratory to the clinic. 
Many promising neuroprotective agents have failed in both basic research and 
clinical trials due to multiple factors, including failure to combine 
pharmacotherapy with vessel reperfusion, and failure to direct therapy to the 
affected tissue in a timely fashion. With our modified version of the MCAo model 
and potential for selective delivery of agents that could be neuroprotective, 
neuroreparative, barrier-protective, or vasculo-protective, each of these issues is 
addressed. 
 Imitating a thrombus in a large vessel occlusion by kinking the MCA and 
clamping the CCA mimics the large vessel occlusion that is observed clinically. 
Removing the MCA metal wire and CCA clamp restores blood flow to the 
occluded vessel as would be seen clinically with the mechanical retrieval of the 
thrombus. Rapid recanalization of an occluded vessel in acute ischemic stroke is 
paramount. Indeed, speed of recanalization is required by Comprehensive Stroke 
Centers to be reported as a ‘core measure’ to the Joint Commission (JCAHO 07-
22-2014). Retro-engineering our mouse model from the clinical condition while 
incorporating flow rate and injection volume optimization allows us to mimic 
current neurosurgical practices. By bringing our mouse model one step closer to 
what is seen clinically through the addition of intra-arterial drug delivery, we are 
demonstrating current practices for stroke treatment. The flow rate and injection 
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volume studies further mimic what is seen clinically with superselective drug 
delivery, but through optimization of flow rate and injection volume we also 
demonstrated that potential therapeutic compounds could selectively reach the 
site of ischemia for maximal effect and potentially mitigate systemic side effects. 
 In this study, we employed an easily visible carbon black ink mixture to 
optimize volume and flow rates to maximally target ipsilateral stroke brain tissue. 
One potential limitation of this study is that ink is denser than typical 
pharmacologic agents in solution. While this may confound the applicability of 
rate/volume studies, lower density solutions would be expected to travel farther 
with a wider potential distribution (contralateral/systemic); thus, the validated 2.5 
µl/min flow rate and 10 - 25 µl volume would serve as an absolute maximum 
using this technique. Further exploration of our IA model using solutions of 
different densities and viscosities labeled with a real-time measureable tracer 
could be employed for further optimization of flow rate and injection volume. 
Certainly, our flow/distribution experiments do not preclude the need for 
individual agent-specific localization experiments, but rather provide a starting 
point for flow rate and volume limitations for future experiments.  
Conclusion 
 By modifying an already well-established mouse stroke model and 
adapting it to mimic current clinical stroke treatment, we have developed a novel 
method of IA drug delivery for potential therapeutic compounds that may limit 
systemic side effects, enable early pharmacotherapy, and provide methodology 
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for testing the role of acutely administered compounds for neuroprotection and 
neuro-repair in acute ischemic stroke. In closing, our model of IA 
pharmacotherapy delivery has shown promise in the MCAo stroke model but 
could easily be adapted to most mouse models of stroke.  
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Chapter Three: Intra-arterial Nitroglycerin 
Maniskas ME, Roberts JM, Trueman R, Learoyd A, Gorman A, Fraser JF, Bix 
GJ. Intra-arterial nitroglycerin as directed acute treatment in experimental 
ischemic stroke. J NeuroInterventional Surgery. (In review) 
 
Introduction 
 Stroke is defined as the disruption of blood flow to the brain due to 
vascular occlusion (ischemic) or bleeding (hemorrhagic), and is the second 
leading cause of death worldwide and a leading cause of long-term disability 
(59). Emergent large vessel occlusion (ELVO) is the most life-threatening and 
disabling type of ischemic stroke. Treatment options for ELVO consist of 
endovascular thrombectomy (ET) and/or intravenous (IV) tissue plasminogen 
activator (t-PA), but not all patients are eligible due to exclusion criteria (10, 60-
62). Furthermore, while ET and IV t-PA have improved patient survival, there is a 
need for adjunctive therapies to be used in tandem with or as a standalone 
following successful vessel recanalization (38). These adjunctive therapies could 
target specific aspects of the apoptotic cascade that occurs when the brain is 
deprived of oxygen and glucose. Furthermore, any potential pharmacotherapy 
administration may be most successful and cause fewer systemic side effects if it 
is targeted to the site of ischemia. We hypothesize that improved treatment for 
ELVO could include rapid recanalization of the occluded vessel via ET combined 
with acute pharmacotherapy directed to the site of ischemia. To test such a 
targeted therapeutic approach, our lab uses an intra-arterial (IA) experimental 
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model of pharmacotherapy administration in combination with transient tandem 
ipsilateral common carotid artery (CCA) and middle cerebral artery (MCA) 
occlusion, hereafter referred to as MCAo (63). 
 Using the already exposed vasculature of the MCAo we are able to 
selectively administer our drug of choice IA further mimicking the human clinical 
condition of pharmacotherapy delivery. Combining the two methods allows us to 
mimic an acute ischemic stroke but also guarantee successful recanalization 
followed by drug delivery in a timely manner similar to ET. Thus far, we have 
successfully optimized our IA model to determine a flow rate of 2.5 μl/min with an 
injection volume of 10 μl.   
 In this study, we chose to investigate the therapeutic potential of acute IA 
administration of nitroglycerin or glyceryl trinitrate (GTN) in our experimental 
stroke model. GTN is an FDA approved vasodilator for angina pectoris and high 
blood pressure that was recently studied in the Efficacy of Nitric Oxide in Stroke 
(ENOS) ischemic stroke clinical trial (41, 43, 64). This study investigated the 
potential of GTN to reduce blood pressure and improve functional outcome 
following acute ischemic stroke with treatment through a systemic sustained 
release transdermal patch. Results showed a reduction in blood pressure on 
post-stroke days 1 and 7 but no improvement in functional outcome at day 90 
(41, 43, 65). Individuals suffering a stroke are at an elevated risk of increased 
intracranial pressure (ICP); a reduction in ICP either through direct (IA) or indirect 
(patch) administration to the cerebrovasculature could improve outcome (66). 
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The ENOS trial acutely reduced blood pressure and by doing so appeared to 
have a neuroprotective effect but failed to show improvement beyond blood 
pressure reduction. These results could be directly tied to GTN’s short half-life 
and inability to reach the cerebrovasculature if applied as a patch on the arm or 
chest.  
Material and Methods 
 Experiments were performed in accordance with protocols on file with the 
University of Kentucky Division of Laboratory Animal Research, Institutional Care 
and Use Committee and ARRIVE Guidelines (67). In short, 16 week old C57/Bl6 
(25 - 30 grams) male mice from Jackson Laboratories were administered GTN 
(American Reagents) diluted in vehicle (water - 39.5%, ethyl alcohol - 30%, 
propylene glycol - 30%) or vehicle only IA four minutes following MCAo. Animals 
were grouped into naïve (age matched litter mate controls exempted from 
surgery and anesthesia), control (MCAo surgery with IA injection of vehicle 
through Internal Carotid Artery (ICA)), and treated (MCAo surgery with IA 
injection of 3.1, 6.2, 12.5, 25 and 50 µg/µl GTN in 10μl injection volume through 
the ICA). GTN was administered in a dose escalating fashion to determine safety 
and efficacy, as there is no standard dose of IA GTN and thus a dose response 
study was necessary to determine safety. Previous flow rate and injection volume 
studies determined the optimal flow rate of 2.5µl/min and injection volume of 10µl 
per mouse (63). Subjects were numerically labelled in a randomized blinded 
fashion for Laser Doppler flowmetry, infarct volume measurement, functional 
   
 
41 
 
outcome assessment and brain immunohistochemistry. Exclusion criteria are as 
follows: rupture of the MCA following wire placement and/or removal, rupture of 
CCA following clamp placement and/or removal, inability to place tubing in the 
ECA, leakage of tubing around the ECA upon pumping, failure of animal to 
recover from surgery resulting in death, death of animal during study, signs of 
hemorrhage upon brain extraction (5 animals were excluded based on 
aforementioned criteria). Our MCAo and IA model of pharmacotherapy 
administration have a death rate of <5% in both surgery and behavior (63).  
Animal Number 
 The experiment was conducted using 50 animals (5 groups), naïve 
animals were excluded from Laser Doppler and MouseOx. For Laser Doppler 
and MouseOx (n = 5/group), infarct volume measurements (n = 10/group), 
functional outcome assessment (n = 6/group), blood draws (vehicle n = 2, treated 
n = 5), and brain immunohistochemistry (n = 5/group).  
Vital Sign Measurements 
 Physiological measurements (heart rate – beats per minute (bpm)) and 
blood pressure (pulse distention – micrometer (µm)) were taken on animals only 
undergoing the IA surgery (no MCAo surgery) over a 20 minute period, beginning 
at IA injection and continuous through 20 minute mark. Measurements were 
taken using the MouseOx Plus (Starr Life Science), where a thigh sensor was 
placed on the shaved left thigh of an anesthetized mouse. 
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Perfusion 
 Blood flow through the MCA was measured using the Laser Doppler 
Periflux System 5000 with a 2 mm tip (Perimed). Blood flow measurements were 
taken pre-occlusion (no CCA clamp or MCA metal wire filament insertion), post-
occlusion (CCA clamp and MCA metal wire filament insertion) and 15 minutes 
post-IA injection (pre-occlusion conditions).   
MCAo and IA Injection 
 Using a weight based ratio of Ketamine and Xylazine mixture, animals 
were anesthetized for the MCAo and IA injection procedure. Focal cerebral 
ischemia was induced using our previously described method (37, 38, 40, 63). 
MCAo procedure was for one hour with pre/post-occlusion and recanalization 
confirmed through Laser Doppler flowmetry. To maintain body temperature, 
animals were placed on an elevated stage over a heating pad with core 
temperature measurements taken using the MouseOx Plus (rectal thermometer). 
Following MCAo and IA injection animals were placed in a recovery cage 
warmed by a heating pad and overhead lamp until fully recovered.  
 GTN IA injection followed our previously published protocol (38, 63). In 
brief, a midline incision was made from mandible to sternum exposing and 
isolating the CCA, ECA and ICA. The ECA was permanently occluded with 4-0 
suture at its distal end and the ICA was temporarily occluded. Using a pair of 
micro scissors, a small nick was made in the ECA midway between the CCA 
bifurcation and proximal suture. Micro-angio tubing was inserted into the ECA 
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through the nick and placed at the bifurcation and suture was used to secure the 
tubing into the ECA. Following un-occlusion of the MCA, CCA and ICA flow was 
restored and the vessel was allowed to recanalize for 5 minutes. Next, IA 
injection of either GTN or vehicle was introduced at a flow rate of 2.5µl/min at a 
volume of 10 µl (38, 63). Once the injection was complete the ECA was 
permanently occluded at its proximal end with a third 4-0 suture and the animal 
was sutured closed.  
Behavioral Testing 
 Animals were subjected to rotor rod (forced motor movement) to 
determine functional ability following surgery and pharmacotherapy 
administration. Animals, naïve, control and treated were trained for three days 
prior to stroke surgery and tested three days following stroke surgery. Rotor rod 
was used to determine percent change from baseline over a 5 minute interval 
with an accelerating rod from 0 – 40 rpms for three trials.  
Infarct Volume 
 On post-stroke day (PSD) 7 mice were euthanized via cervical dislocation, 
the whole brain was removed and flash frozen, sectioned on a cryostat (20 µm) 
and stained using cresyl violet. Infarct volume was analyzed from scanned cresyl 
violet sections with Image J software (NIH) (38).  
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Blood Draws 
 To measure nitric oxide (NOx) levels in the blood, submandibular blood 
draws were performed one day prior to stroke (baseline), post-15 minute IA and 
PSD 1. In short, animals were placed in the dorsal position with their head tilted 
either right or left to expose the ramus of the mandible and submandibular vein 
(68). A 5 mm Golden Rod animal lancet was used to pierce the submandibular 
vein, blood (10% of total animal blood volume) was collected in an EDTA tube, 
and centrifuged at 14,000 rpm for 15 minutes. Plasma was collected and 
analyzed for NOx levels.  
Nitric Oxide (NOx) Analysis 
 Nitrate reductase was used to reduce nitrate to nitrite in blood plasma 
samples. A volume of 5 µl nitrate reductase and 5 µl of co-factor (Nitrite/Nitrate 
Assay Kit, Sigma-Aldrich, UK) was added to 40 µl plasma and incubated for 2 
hours at 25°C. Nitrate/nitrite (NOx) concentration were then determined using 
Sievers Nitric Oxide Analyzer (NOA 280i; GE Instruments, UK). During this 
procedure the nitrite was reduced to nitric oxide by acetic acid. Nitric oxide was 
then quantified using ozone-chemiluminescence technology.  
Immunohistochemistry 
 Whole brains flash frozen were sectioned on a Leica CM 1950 cryostat at 
20 µm and mounted on slides. Glial Fibrillary Activating Protein (GFAP 1:500 
antibody dilution, Sigma) immunohistochemistry was used to evaluate 
astrogliosis. NeuN (1:500 antibody dilution, Abcam) immunohistochemistry was 
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used to analyze mature neuron survival in the stroke affected region (core and 
penumbra). Infarct and peri-infarct regions (defined as a 500-µm boundary 
extending from the edge of the infarct core, medial and lateral to the infarct of the 
cortex) were identified histologically after cryostat sectioning. Stains were imaged 
with a Nikon Eclipse Ti microscope at 20X magnification and images collected 
with a CCD camera and devoted computer qualified with Adobe Photoshop. 
Nikon NIS Element BR Analysis imaging software was used to analyze positive 
pixel density of sectioned brains from naïve, control and treated groups.  
Statistical Analysis 
 Measured variables are shown as mean ± Standard Error of the Mean 
(SEM). Analysis of results for comparison between treatment groups (infarct 
volume, immunohistochemistry) was performed using a Student’s t-test. Time 
course comparisons (behavior) and NOx were analyzed using a Two-Way 
Repeated Measures ANOVA. We defined significance as *P ≤ 0.05, **P ≤ 0.01, 
and ***P ≤ 0.001. 
Compliance with STAIR Criteria 
 To maximize the applicability of our results, we designed the study with 
reference to the STAIR recommendations for preclinical neuroprotection 
research (69). We performed a dose response to determine if there was a 
deleterious dose and found all animals’ survived IA GTN injections.  
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Results 
Vital Sign Measurements 
 Physiological measurements for heart rate (IA injection only) 
demonstrated no difference from baseline for all groups except 6.2 µg/µl which 
showed a significant reduction in beats per minute at post-IA to 15 minutes post-
IA. The animals in the 6.2 µg/µl group recovered without incident despite a 
lowered heart rate. Pulse distention showed no difference between groups from 
baseline with all animals recovering without incident. Data not shown.  
Perfusion 
 Perfusion measurements using the Laser Doppler were made at baseline, 
occlusion, and 15 minutes post-IA to determine whether IA GTN had any effect 
on the MCA perfusion. We demonstrated an 83% reduction in cortical blood flow 
through the MCA post occlusion. Following un-occlusion and 5 minute 
recanalization, GTN and vehicle were administered IA and measured 15 minutes 
post-IA. While all groups increased perfusion through the MCA there was no 
significant difference between GTN doses and vehicle 15 minutes post-IA 
injection over the time period analyzed (Figure 3.1).  
Infarct Volume 
 Infarct volume (Figure 3.2 A) was assessed using cresyl violet (Figure 3.2 
B) and analyzed on PSD 7 using Image J. Mean infarct volumes (mm3) 
demonstrated a dose response effect compared to control, with 12.5 µg/µl  
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INTRA-ARTERIAL NITROGLYCERIN STROKE PERFUSION 
MEASUREMENTS  
Figure 3.1. Laser Doppler blood perfusion through middle cerebral 
artery at time point 0 minutes (baseline measurements), 5 minutes 
(occlusion), and 75 minutes (drug administration/reperfusion). 
Vehicle (n = 5), 3.1 µg/µl (n = 5), 6.2 µg/µl (n = 5) and 12.5 µg/µl 
(n = 5) 
*** 
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3.1 ug 6.2 ug 25 ug 12.5 ug Vehicle 
Figure 3.2. A. Infarct volume analysis for vehicle versus GTN treatment (3.1, 6.2, 12.5, and 25 µg/µl) using 
cresyl violet stained stroked tissue., B. Cresyl violet image for vehicle group., C. Cresyl violet image for 3.1 
µg/µl group., D. Cresyl violet image for 6.2 µg/µl group., E. Cresyl violet image for 12.5µg/µl group., F. Cresyl 
violet image for 25 µg/µl group. Vehicle (n = 20), 3.12 µg/µl (n = 4), 6.2 µg/µl (n = 4), 12.5  µg/µl (n = 4), and 
25 µg/µl (n = 4).  * indicates P < 0.05 and ** indicates P < 0.001. 
A B C D E F 
INTRA-ARTERIAL NITROGLYCERIN INFARCT VOLUME MEASUREMENTS AND IMAGES 
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showing a significant decrease in infarct volume. However, the 25 µg/µl dose 
showed signs of hemorrhage and an infarct volume similar to vehicle control. 
Behavioral Testing 
 In addition to infarct volume assessment, we performed rotor rod 
functional analysis on all of the groups except the less well-tolerated 25 µg/µl 
dose. Functional assessment of IA GTN on the rotor rod (forced motor 
movement) was measured in percent change from baseline on PSD 1, 3 and 7 
(Figure 3.3). On PSD 1 the control stroked group showed a decrease from 
baseline (-27.25 ± 13.42) as expected while the naïve group without any brain 
injury significantly improved (21.10 ± 31.43) as expected compared to control. 
GTN doses of 3.1 and 6.2 µg/µl showed a significant (P < 0.001) improvement 
(23.48 +/- 35.30 and 30.51 ± 25.06) from control, while the 12.5 µg/µl GTN dose 
was slightly less than baseline (-7.36 ± 24.52).  
 On PSD 3, the control group, while still reduced from baseline (-12.65 ± 
32.51), did improve slightly from PSD 1 measurements, while the naïve group 
continued to significantly increase from baseline (44.30 ± 43.21) and PSD 1 
compared to control. However, the GTN dose of 3.1 µg/µl (20.75 ± 19.04) 
remained above baseline but was slightly less than PSD 1 measurements. GTN 
group 6.2 µg/µl (36.73 ± 27.2) continued to improve from baseline and PSD 1 
measurements, and 12.5 µg/µl (51.77 ± 32.29) improved significantly from PSD 1 
measurements. 
  
   
 
50 
 
INTRA-ARTERIAL NITROGLYCERIN BEHAVIORAL MEASUREMENTS  
  
Figure 3.3. Behavioral measurements for Rotor Rod for Control 
(vehicle), Naïve, 3.1 µg/µl, 6.2 µg/µl and 12.5 µg/µl GTN. Control 
(black dotted line), Naïve (red dashed line), 3.1 µg/µl (green line), 
6.2 µg/µl (grey line), and 12.5 µg/µl (blue line). Control (n = 5), 3.1 
µg/µl (n = 5), 6.2 µg/µl (n = 5) and 12.5 µg/µl (n = 5). * indicates P 
< 0.05 (3.1 µg/µl versus vehicle), # indicates P < 0.05 (6.2 µg/µl 
versus vehicle) 
* 
# 
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 On PSD 7, the control group, decreased from both baseline and PSD 3 (-
26.11 ± 26.88), while the naïve group continued to significantly increase from 
baseline (51.10 ± 33.41) and PSD 1 compared to control. However, the GTN 
dose of 3.1 µg/µl (10.51 ± 22.91) remained above baseline measurements but 
was slightly less that its PSD 1 and 3 measurements. 6.2 µg/µl (35.59 ± 26.63) 
and 12.5 µg/µl (32.34 ± 37.79) GTN doses continued to improve from baseline 
and their PSD1 values. However, none of the GTN dose measurements were 
significantly greater than the control by PSD 7.   
Blood Nitric Oxide (NOx) Measurements 
 Next, as one of the goals of the IA administration of GTN after stroke was 
to limit systemic effects, we investigated whether such IA GTN administration 
had any effect on blood nitric oxide (NOx) levels. Compared to baseline blood 
draws, blood NOx levels were elevated 15 minutes after either IA vehicle or GTN 
treated groups, the latter being slightly, but not significantly, more elevated. By 
PSD 1, blood NOx remained similarly elevated from baseline pre-stroke levels in 
both groups (Figure 3.4).  
Immunohistochemistry 
 Antibodies specific to proteins associated with mature neuron survival 
(NeuN) (Figure 3.5 A -E), and astrocytic activation (GFAP) (Figure 3.5 F -J). 
Compared to control, GTN treated animals showed a dose response stair step 
effect with a significant (P < 0.001) increase in NeuN positive pixels at doses 3.1,  
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6.2, and 12.5 µg/µl. Likewise, a similar stair step dose response was seen in GFAP 
with control having a significantly (P < 0.001) increased number of GFAP positive 
pixels compared to GTN doses.  
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INTRA-ARTERIAL NITROGLYCERIN BLOOD NITRIC OXIDE ANALYSIS 
  
Figure 3.4. Blood NOx levels of GTN (12.5 µg/µl) versus 
control post-IA and Day 1. Treated (n = 2), Control (n = 
5) 
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Figure 3.5. Graphs and images for immunohistochemistry magnification at 20X with quantification of positive pixel 
density. A. Graph depicting positive pixel for NeuN stain of vehicle versus GTN (3.1, 6.2, and 12.5 µg/µl) in infarcted 
region., B. Image of vehicle NeuN stain from infarcted region at magnification 20X., C. Image of 3.1 ug/ul NeuN stain 
from infarcted region at magnification 20X., D. Image of 6.2 µg/µl NeuN stain from infarcted region at magnification 
20X., E. Image of 12.5 µg/µl NeuN stain from infarcted region at magnification 20X., F. Graph depicting positive pixel 
density for GFAP stain of vehicle versus GTN (3.1, 6.2, and 12.5 µg/µl) in infarcted region., G. Image of vehicle 
GFAP stain from infarcted region at 20X., H. Image of 3.1 ug/ul GFAP stain from infarcted region at magnification 
20X., I. Image of 6.2 µg/µl GFAP stain from infarcted region at magnification 20X., J. Image of 12.5 µg/µl GFAP stain 
from infarcted region at magnification 20X. Vehicle (n = 4), 3.1 µg/µl (n =4), 6.2 µg/µl (n = 4) and 12.5 µg/µl (n = 4) 
White scale bar, 100µm. ** indicates P < 0.001, *** indication P < 0.001 
A 
F 
B C D E 
H I J G 
INTRA-ARTERIAL NITROGLYCERIN IMMUNOHISTOCHEMISTRY GRAPH AND IMAGES 
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Discussion 
 Stroke remains a world-wide leading cause of mortality and morbidity with 
limited therapeutic options. Currently, IV t-PA is the only approved 
pharmacotherapy available but extensive exclusion criteria limits its use to less 
than 16% of those affected by stroke. With the recently completed and 
successful ET trials for ELVO such as MR Clean trial, ET can be used to rapidly 
recanalize stroke through IA access. This provides a clinical/translational 
opportunity to co-administer potential neuroprotective compounds. Using a 
clinically relevant mouse model of stroke (MCAo), we have developed a novel 
method of IA (similar to ET) pharmacotherapy delivery that allows us to deliver 
selected compound directly to the site of ischemia while mitigating systemic side-
effects (38).  
 Glyceryl trinitrate or GTN was used in the recently completed ENOS trial 
and shown to be safe when administered in patch form following stroke. The 
outcome of the trial was an acute reduction in blood pressure, but no 
improvement in functional outcome (41, 65, 66). GTN is a known vasodilator and 
is commonly used to treat ischemic heart disease, but we and others believe it 
may also have significant neuroprotective properties as discussed below. 
Therefore, our goal in this study was to target GTN directly to the site of the 
stroke via our IA model of pharmacotherapy administration following MCAo to 
evaluate these potential neuroprotective properties.  
 Since there is not a standard IA dose of GTN available we started with a 
dose-response evaluation (3.1, 6.2, 12.5 and 25 µg/µl) to determine if IA GTN 
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was safe (no bleeding into the parenchyma) and had an effect on infarct volume. 
Our study showed the mice tolerated and survived IA GTN with no overt 
deleterious effects, and there was a positive dose-dependent effect on infarct 
volume with a significant reduction noted with the 12.5 µg/µl dose. However, the 
25 µg/µl dose had bleeding into the ventricles and an infarct volume similar to 
vehicle control. Therefore, we conclude that IA GTN is a safe potential 
neurotherapeutic with a specific toxicity profile, which includes intraventricular 
hemorrhage at the highest dose tested. Additional studies should further 
delineate the effective dose-response therapeutic window.  
 We evaluated the potential effect of IA GTN on functional outcome. While 
the lower doses (3.1 and 6.2 µg/µl) had initial significant positive effects 
immediately following infarct induction on PSD 1, these effects disappeared by 
PSD 7. Overall, there was no difference among groups in functional outcome. 
This may be due, in part, to GTN’s very short half-life (1.5 - 7.5 minutes) such 
that noted beneficial effects on infarct volume and neuronal viability (and 
decreased reactive gliosis) were not sufficiently pervasive to result in long-term 
functional benefit. In further support of such a conclusion, one potential mediator 
of GTN neuroprotection, NOx (discussed in greater detail below (70-72)), also 
has as extremely short half-life of 2 - 6 seconds. We expect that further studies 
with post-stroke IA GTN, or perhaps combining IA-GTN with other potential, 
longer lasting neuroprotective agents that more thoroughly test functional 
outcome using multiple assessment tools may demonstrate functional benefits.  
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 While we saw no effects of IA GTN on animal pulse distention, there 
needs to be further examination of potential systemic-effects from IA GTN 
administration; therefore, we measured post-stroke blood NOx levels at several 
points after IA GTN or vehicle administration. NOx is a good measure of IA GTN 
administration because GTN is converted to NOx by endothelial nitric oxide 
synthase (eNOS) and released into the blood stream from the vascular 
endothelium. Ultimately, we noted a transient, but insignificant increase in blood 
NOx levels with IA GTN treatment, results that are consistent with efficacious 
GTN delivery and suggest a potential mechanism of action, while simultaneously 
further demonstrating a relative lack of systemic effects with IA GTN treatment.  
 It has been known for decades that GTN has both neuroprotective and 
neurotoxic properties, depending upon whether it is present in physiologic or 
pathologic concentrations, respectively. Post-stroke GTN mediated 
neuroprotection may result from vasodilation of the effected vasculature which 
leads to increased blood flow and return of nutrients. Nitric oxide has been 
shown to be neuroprotective through vessel dilation, anti-apoptotic mechanisms 
as a reactive oxygen species scavenger, and through inhibition of lipid 
peroxidation sustaining cellular membrane integrity (71, 73-75). In our study, we 
noted transient, but insignificant increases in both MCA vasodilation and blood 
NOx levels with IA GTN treatment. While IA GTN’s mechanism of action may be 
a combined effect (vasodilation and production of nitric oxide species), one 
additional possibility is that IA GTN may have increased local NOx levels in the 
stroke-targeted brain, an analysis that should be performed in additional studies. 
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Collectively, despite the limitations of this study, our results suggest a novel 
therapeutic modality of GTN that, independent of its blood pressure lowering 
effects, may be of benefit after ischemic stroke with further study.  
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Chapter Four: Intra-arterial Verapamil 
Maniskas ME, Roberts JM, Aron I, Fraser JF, Bix GJ. Stroke neuroprotection 
revisited: Intra-arterial verapamil is profoundly neuroprotective in experimental 
acute ischemic stroke. J Cereb Blood Flow Metab. 2015 Oct 2. PubMed PMID: 
26661189. 
Introduction 
 The only FDA-approved pharmacotherapy for acute ischemic stroke is t-
PA, but with a therapeutic window of 4.5 hours and extensive exclusion criteria, 
few patients receive treatment (55, 61). A second and more accessible form of 
therapy is ET that in addition to IV t-PA is now the standard of care (10, 60, 61). 
While both treatments have improved patient survival and rate of good clinical 
outcomes, the magnitude of outcome advancement has not mirrored the 
increasing improvements in the ability to re-open occluded vessels (9, 13, 60). 
This disconnect highlights an urgent need for adjunctive therapies to further 
improve outcomes after effective thrombolysis with t-PA and thrombectomy (12, 
60, 76).  
 Using the MCAo to model ischemic stroke and IA technique to model 
pharmacotherapy administration in mice, we have developed a model that 
mimics the human clinical stroke condition to better test potential neuroprotective 
compounds (37, 40, 63). This method mirrors the clinical scenario of a 
recanalized artery immediately following thrombectomy; it allows us to test the 
feasibility, safety, and efficacy of IA pharmacotherapy immediately following 
thrombectomy, and provides an animal model to reflect the present clinical 
opportunity to infuse agents IA immediately following successful thrombectomy 
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with the patient still on the angiography procedure table. Verapamil, a calcium 
channel blocker (CCB), is FDA approved for angina and arrhythmia (77). 
Previous verapamil stroke studies had mixed results; while some studies support 
its neuroprotective potential, other experiments failed to show a benefit (44-46, 
78). However, in experiments that failed to show benefit, animal models were 
induced with permanent vessel occlusion and/or given the drug in a time interval 
far beyond its likely therapeutic potential (44, 46). Clinically, we hypothesize that 
treatment for ELVO strokes should consist of rapid recanalization of the occluded 
vessel combined with selective pharmacotherapy, i.e. IV or IA t-PA administration 
directly to the site of ischemia (79, 80). Such a stroke-targeted approach could 
greatly optimize the therapeutic potential of neuroprotective agents. Therefore, in 
this study we investigated the therapeutic potential of IA verapamil in our 
experimental ischemic stroke.  
Material and Methods 
 All experiments conformed to protocols on file with the University of 
Kentucky Division of Laboratory Animal Research, Institutional Animal Care and 
Use Committee and ARRIVE Guidelines (67). Briefly, 16 week old male C57/Bl6 
mice (25 – 30 gram) from Jackson Laboratories were separated into 3 groups (10 
per group for control and treated, 5 for naïve) in a blinded fashion using 
randomized selection. Groups were divided into naïve (age matched litter mate 
controls excluded from anesthesia and surgery), control (MCAo surgery with 10 
µl saline injection at 2.5 µl/minute IA through ICA) and treated (MCAo surgery 
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with 10 µl saline + verapamil injection IA through ICA). Verapamil was 
administered at a dose of 0.15 milligram (mg) per kilogram (kg) (81, 82). This 
dose was calculated to be similar to 10 mg in a 70 kg person, which is the most 
clinically relevant current IA dose. Prior studies determined the optimal flow rate 
of 2.5 µl/minute with an injection volume of 10 µl per animal (63). Physiological 
measurements, blood flow measurements, behavioral, infarct volume and 
immunohistochemistry analyses were conducted in a blinded fashion with 
experimental subjects numerically labeled. Animals were excluded from the study 
if the MCA or CCA was punctured during wire and clamp insertion or removal, 
died following surgery in recovery or were euthanized before the end of the study 
due to poor health. Overall, there is <5% death rate for our stroke model 
following both surgery and during behavior. 
Animal Numbers 
 The experiment was conducted using 65 animals (3 groups), naïve 
animals were excluded from Laser Doppler and MouseOx. For Perfusion, 
MouseOx and infarct volume (n = 25 for treated and n = 20 for control), and brain 
immunohistochemistry (n = 10 for both control and treated). Additionally, an n of 
5 naïve age matched controls was used for behavioral testing. 
Vital Signs 
 Vital signs were monitored using the MouseOx Plus (Starr Life Science). A 
thigh sensor, placed on the shaved left thigh, was used to measure heart rate 
(beats per minute – bpm) and pulse distention or blood pressure (micrometers - 
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µm) with measurements taken from 0 - 5 minutes for baseline measurements, at 
65 minutes (drug administration) after un-occlusion/reperfusion following 60 
MCAo surgery, at 70 minutes and 75 minutes reperfusion. 
Perfusion 
 Blood flow through the MCA was measured pre and post-occlusion and 
after reperfusion using the Laser Doppler Periflux System 5000 with a 2 mm tip 
and Laser Speckle PeriCam PSI System – Blood Perfusion Imager High 
Resolution (Perimed). To measure occlusion and reperfusion of the MCA, 
measurements were taken before drilling the burr hole (0 minutes), after metal 
wire insertion under MCA (5 minutes) and following 60 minute occlusion with un-
occlusion/reperfusion measurements at 70 (drug administration), 75 and 80 
minutes. Care was taken to ensure the probe was placed in the same location for 
each measurement. To measure hemispheric blood flow the Laser Speckle was 
positioned 8 cm above the exposed pronated mouse skull and set to measure at 
Regions on Interest (ROI) and Time Points of Interest (TOI). The laser guidance 
system positioned along the sagittal suture acted as a landmark to ensure 
consistent measurements. Measurements were taken before occlusion at 0 
minutes, at 5 minutes after occlusion and after reperfusion at 80 minutes which 
included drug administration and 10 minutes of reperfusion.  
MCAo and IA injection 
 Animals were anesthetized using a Ketamine and Xylazine mixture in a 
weight based dosing scale (100 µl of anesthesia for every 10 grams). To induce 
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focal cerebral ischemia, we used the previously described MCAo stroke model 
(37, 40). The occlusion was for a one-hour interval, and recanalization was 
confirmed via Laser Doppler and Speckle. Animals were warmed on a heating 
pad throughout surgery and core temperature (rectal thermometer) monitored 
using the MouseOx Plus (Starr Life Science) to ensure body temperature did not 
drop below recommended levels. Post-surgery, animals were warmed on a 
heating pad with overhead light and checked every 5 minutes to ensure 
hyper/hypothermia did not occur.   
 To infuse IA verapamil, we followed our previously published protocol (63). 
Briefly, we exposed the CCA bifurcation and its branches the ICA and ECA. The 
distal ECA was permanently occluded, the ICA was temporarily occluded, and a 
nick was made with micro scissors in the ECA to allow for micro-angio tube 
insertion and secured with suture. Following the one-hour occlusion the CCA and 
ICA clamps and metal filament under the MCA were removed restoring blood 
flow. After 5 minutes of reperfusion, the study agent (saline or verapamil) was 
infused IA at a rate of 2.5 µl/minute at a volume of 10 µl (63). After the injection 
the proximal ECA was permanently occluded and the incisions in the thoracic 
and temporal region were sutured.  
Behavioral Testing 
Two behavioral tests were performed to assess functional outcome after surgery 
and pharmacotherapy administration: the rotor rod (used to measure forced 
movement) and open field (used to measure free roam). For the rotor rod, 
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animals, naïve (age matched controls, no anesthesia or surgery), control (MCAo 
surgery with IA injection of saline), and treated (MCAo surgery with IA injection of 
verapamil) were trained for 3 days prior to stroke surgery and tested for 3 days 
following stroke surgery: the mice were placed on the rotor rod for 5 minutes with 
an increasing acceleration from 0 – 40 rpm for three trials. Distance covered by 
each animal was measured in percent change from baseline. The open field 
consists of a squared box measuring 50 cm by 50 cm by 30 cm with an infrared 
camera positioned above the box, which tracks the movement of the animals. 
Our parameters were set to measure percent change from baseline. Behavioral 
training occurred on the rotor rod for 3 days prior to stroke (-3, -2 and -1) and on 
post stroke day (PSD) 1, 3, and 7, while the open field testing occurred 1 day 
prior to stroke (-1) and testing on PSD 1 and 7. 
Infarct Volume Analysis 
 The mice were euthanized via cervical dislocation on PSD 7, and the 
whole brain was removed, sectioned using a brain mold into 2 mm sections and 
stained using Triphenyl Tetrazolium Chloride (TTC) for 10 minutes. Infarct 
volume was analyzed from scanned TTC stained brain sections with Image J 
software (NIH). Whole brains were flash frozen, sectioned on the cryostat and 
stained with Cresyl Violet for additional infarct volume analysis as described 
below under immunohistochemistry.  
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Immunohistochemistry 
 Flash frozen whole brains were sectioned on a Leica CM 1950 cryostat at 
20 µm and mounted on slides. Infarct volume and overall neuronal health was 
assessed by TUNEL stain (Millipore). Astrogliosis was assessed with Glial 
Fibrillary Activating Protein (GFAP 1:1000 antibody dilution, Sigma) 
immunohistochemistry. Mature neuron survival within the stroke affected area 
was assessed via NeuN (1:1000 antibody dilution, Abcam) 
immunohistochemistry.  Area of infarct analysis corresponds to cortical region 
that was the epicenter of the stroke morphologically identified based on cryostat 
sectioning to include greatest affected area. Stains were visualized with a Nikon 
Ecliplse Ti microscope at 20X magnification and images collected via CCD 
camera and attached to computer qualified with Adobe Photoshop. Nikon NIS 
Element BR Analysis imaging software was used to analyze brain sections from 
control and treated groups, sections were plated 4 to a slide with 10 slides per 
animal for a total of 40 sections.  
Statistical Analysis 
 All measured variables are presented as mean ± SEM. We selected rotor 
rod as the primary endpoint for power calculations because it had the smallest 
anticipated effect size. Based on an anticipated effect size of 1.0 (Cohen’s d) and 
significance level of 0.05, we expected to have 81% power with 17 animals per 
group to detect improvement from day 1 to day 7 post-surgery. We increased the 
sample sizes in each group to bolster power and account for potential losses. 
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Based on preliminary data, we expected close 100% power to detect differences 
in infarct volume (anticipated Cohen’s d = 3.4) using these same groups. 
Analysis of results for comparison between treatment groups (infarct volume, 
immunohistochemistry) was performed using a Student’s t-test. For time course 
comparisons (behavior, vital signs and perfusion), a Two-Way Repeated 
Measures ANOVA was used. Significance is defined as a * P ≤ 0.05, ** P ≤ 0.01, 
*** P ≤ 0.001. 
Compliance with STAIR Criteria 
To maximize the applicability of our results, we designed the study with reference 
to the STAIR recommendations for preclinical neuroprotection research (69). 
With regard to dose of drug, we selected a weight-based dose-equivalent to 10 
mg in a 70-kg human. This is the dose used currently by endovascular 
neurointerventionalists to treat patients in the angiography suite. We have not yet 
conducted preclinical dose-response studies. In terms of window of opportunity, 
we administered the drug in immediate sequence after vessel reperfusion in 
order to simulate the clinical scenario of IA administration immediately following 
thrombectomy. We conducted the experiments in a blinded fashion, with 
randomization of assignment to treatment groups. We conducted a power 
analysis to ensure adequate subject numbers as detailed. We performed 
physiologic monitoring as detailed, and achieved Laser Doppler flow reduction 
≥60% as detailed in results. Regarding outcome measures, we evaluated 
functional outcome and infarct volume, as well as immunohistochemistry analysis 
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of infarct. We did not analyze gender or age differences in this study, but such 
analysis is planned for future study.  
Results 
Vital Signs 
 Measurements of baseline heart rate (bpm) for control and treated groups 
(Figure 4.1A), combined prior to drug injection at 0 minutes (227 +/- 2.92) and 5 
minutes (210 +/- 8.08), demonstrated a non-significant decrease of 67 bpm over 
this time period. Five minutes after recanalization and initiation of IA drug 
administration (i.e. at 70 minutes), the verapamil treated group had a significantly 
(P < 0.001) higher heart rate (218.37 +/- 3.83 vs. 134.00 +/- 1.02 in controls), a 
difference that largely persisted at the time (75 min) of final measurements 
(202.20 +/- 7.04 vs. 125.70 +/- 1.36). 
 Similarly, combined baseline pulse distention (µm) (Figure 4.1B) 
measurements (µm) at 0 minutes (34 +/- 0.23) and 5 minutes (32 +/- 0.61) 
decreased slightly by 2 µm over this time period. At 70 minutes the control group 
had a non-significant increase in pulse distention (24.15 +/- 0.68 vs. 21.60 +/- 
0.69), a difference that became significant (P < 0.001) at 75 minutes (31.45 +/- 
1.54 vs. 22.23 +/- 1.51). 
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Cerebral Blood Flow 
 Five minutes after vessel occlusion, Laser Doppler (Figure 4.2A) blood 
flow measurements (Perfusion Units) through the MCA were reduced to 
approximately 17% of the pre-occlusion value. Reperfusion at 65 minutes  
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 INTRA-ARTERIAL VERAPAMIL PHYSIOLOGICAL MEASUREMENTS 
Figure 4.1. MouseOx Plus Physiological Measurements for Combined 
(black), Treated (red) and Control (blue) groups. Arrow indicates drug 
administration after reperfusion/un-occlusion for 5 minutes. A. Heart Rate 
in beats per minute (bpm), 0 - 5 minutes (baseline measurements), 65 
minutes (reperfusion/un-occlusion and drug administration), 70 and 75 
minutes (reperfusion)., B. Pulse Distention measuring vessel diameter 
(micrometers or μm), 0 - 5 minutes (baseline), 65 minutes 
(reperfusion/un-occlusion and drug administration), 70 and 75 minutes 
(reperfusion). Combined (N = 30), Control (n = 15), Treated (n = 15). 
A 
B 
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demonstrated a 78.71% restoration of flow with a gradual and similar (i.e. not 
significantly different) return to pre-occlusion levels by 75 minutes after occlusion 
regardless of control or verapamil treatment.  
 Similarly, Laser Speckle images (Figure 4.2B) and corresponding graph 
(Figure 4.2C) for equilateral cerebral blood flow measurements (Perfusion Units) 
demonstrated an expected reduction of the ipsilateral cerebral hemisphere 5 
minutes after occlusion with non-significantly different restoration in blood flow 
measurements in the two treatment groups at 80 minutes post occlusion.   
Behavioral Testing 
 Behavioral testing for forced motor (rotor rod) movement (Figure 3.3A) 
was measured using percent change from baseline. On the day following surgery 
and drug administration (PSD 1), the two treatment groups showed no significant 
difference in performance (control 0.86 ± 13.92 vs. treated -10.28 ±- 15.35), but 
were significantly (P < 0.05) different from naïve (23.71 ± 5.48). Treatment 
groups separated and were significantly (P < 0.01 and P < 0.001) different on 
PSD 3 (control -31.68 ±- 15.96 vs. treated 16.70 ± 9.81), and PSD 7 (control -
60.20 ± 20.72 vs treated 24.70 ± 8.23). Naïve was not significantly different from 
treated on PSD 3 (25.31 ± 12.51) and PSD 7 (29.31 ± 19.51) but was significant 
from control (P < 0.01 and P < 0.001). 
 In the free roam motor (open field) movement (Figure 3.3B), analysis was 
measured in percent change from baseline (measurements for 5 minutes). Both 
groups had a significant (P < 0.001) decrease in free roam movement  
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INTRA-ARTERIAL VERAPAMIL PERFUSION MEASUREMENTS 
Figure 4.2. Perfusion Measurements for Combined (black), Treated (red) 
and Control (blue) groups. Arrow indicates drug administration after 
reperfusion/un-occlusion for 5 minutes. A. Laser Doppler blood perfusion 
through middle cerebral artery at time points 0 minutes (baseline 
measurements), 5 minutes (occlusion), 70 minutes (reperfusion/un-
occlusion) and 75 and 80 minutes (reperfusion) Treated (n = 9). Control 
(n = 9)., B. Laser Speckle whole brain perfusion images through 
contralateral and ipsilateral cortex at time points 0 minutes (Baseline), 5 
minutes (MCA occlusion) and 80 minutes (Reperfusion) for Treated (n = 
3) and Control (n = 3). Black circles indicate Regions of Interest, 
Ipsilateral (I) and corresponding Contralateral (C) for MCA occlusion at 
aforementioned time points. C. Laser Speckle graph for whole brain 
perfusion through contralateral and ipsilateral cortex at time points 0 
minutes (baseline measurements), 5 minutes (MCA occlusion) and 80 
(15 minutes reperfusion/un-occlusion) Treated (n = 3), Control (n = 3). 
A 
B 
C 
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INTRA-ARTERIAL VERAPAMIL BEHAVIORAL MEASUREMENTS 
  
Figure 4.3. Behavioral measurements for Rotor Rod and Open Field for Naive 
(gray), Treated (red) and Control (blue) groups. A. Rotor Rod is a forced motor 
movement test and recorded in percent change from baseline, treatment groups 
separated following stroke surgery into control, treated and naive and were 
tested on days (1, 3, and 7)., B. Open Field free roam movement, groups 
separated into control, treated and naive groups on PSD 1 and 7. Combined (N 
=49), Treated (n = 25), Control (n = 20), Naive (n = 5). # indicates P < 0.05 for 
naïve versus treated/ control, && indicates P < 0.01 for treated/naïve versus 
control, &&& indicates P < 0.001 for treated/naïve versus control, ### indicates 
P < 0.001 for naïve versus treated/control, ** indicates P < 0.01 for treated 
versus control.  
   
 
73 
 
 
on PSD 1 (control -108.73 ± 9.03 vs. treated -92.39 ± 17.67) when compared to 
baseline and naïve (9.01 ± 3.75). By PSD 7 the treated group moved significantly 
(P < 0.05) more (control -109.81 ± 4.36 vs. treated -84.00 ± 17.41) but both 
groups were significantly (P < 0.01) less than naïve (-33.17 ± 10.18).   
 Both groups significantly (P < 0.001) decreased in overall distance 
covered on PSD 1 compared to baseline and naïve, there was no significant 
difference between baseline and naïve (9%) from baseline to PSD 1. Finally, 
while control stroked mice open field performance remained significantly (P < 
0.001) worse than naïve, aged matched control mice on PSD 7, IA verapamil 
treated group performance recovered but was still significantly (P < 0.01) 
decreased from naïve. 
Infarct Volume 
 Infarct volume was analyzed using two forms of measurements; TTC and 
Cresyl Violet infarcts were combined and analyzed on PSD 7 (Figure 4.4). Mean 
infarct volumes (mm3) were significantly different (P < 0.001) between the control 
group (17.46 +/- 2.66) and treated (0.64 +/- 0.35). 
Immunohistochemistry 
 Specific antibodies were used for proteins related to overall cellular health 
(TUNEL stain) (Figure 3.5 A – C), astrocytic inflammation/infiltration (GFAP) 
(Figure 3.5 D - F) and neuron survival (NeuN) (Figure 3.5 G - I). Compared to  
 
 
 
 
7
4
 
 
 
 
Figure 4.4. A. Infarct volume analysis for control versus treated using TTC 
and cresyl violet stained stroked tissue. Treated (n = 18) Control (n = 15)., 
B. TTC image for control group., C. TTC image for treated. *** indicates P 
≤ 0.001. 
A B C 
Control Treated 
INTRA-ARTERIAL VERAPAMIL INFARCT VOLUME ANALYSIS 
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INTRA-ARTERIAL VERAPAMIL IMMUNOHISTOCHEMISTRY 
  
Figure 4.5. Graphs and images for immunohistochemistry, 
magnification at 20X with quantification of positive pixel density. A. 
Graph depicting positive pixel for TUNEL stain of control versus 
treated in infarcted region., B. Image of control TUNEL stain from 
infarcted region at magnification 20X., C. Image of treated TUNEL 
stain from infarcted region at magnification 20X., D. Graph depicting 
positive pixels for GFAP stain of control versus treated in infarcted 
region., E. Image of control GFAP stain from infarcted region at 
magnification 20X., F. Image of treated GFAP stain from infarcted 
region at magnification 20X., G. Graph depicting positive pixels for 
NeuN stain of control versus treated in infarcted region., H. Image of 
control NeuN stain from infarcted region at magnification 20X., I. 
Image of control and treated NeuN stain from infarcted region at 
magnification 20X. Treated (n = 10), Control (n = 10). White scale 
bar, 100μm. *** indicates P ≤ 0.001. 
A 
D 
G 
E F 
C B 
I H 
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treated animals, there was a significantly greater increase in TUNEL positive 
pixel density in control groups (P < 0.001). Likewise, GFAP 
immunohistochemistry demonstrated significantly more GFAP immunoreactivity 
in the infarcted brain of control animals (P < 0.001). Lastly, NeuN 
immunohistochemistry demonstrated significantly decreased NeuN 
immunoreactivity in the infarcted brains of control animals (P < 0.001). 
Importantly, as mentioned in the methods section, the area of brain analyzed in 
these studies corresponds to the cortical region that was the epicenter of the 
stroke morphologically identified based on cryostat sectioning to include the 
greatest affected area 
Discussion 
 Stroke remains a leading cause of morbidity and mortality in the United 
States. However, with advances in vessel recanalization with t-PA and 
endovascular thrombectomy there is a greater chance of stroke survival and 
opportunity to decrease long-term disability. We believe that targeted IA delivery 
of a potential neuroprotective compound into the just recanalized large cerebral 
blood vessel is the next logical step in clinically acute ischemic stroke care. Our 
lab uses a clinically relevant mouse model of stroke to induce a focused, reliable 
and reproducible cortical infarct that similarly affects motor function as seen 
clinically. Following vessel recanalization we IA administered the potentially 
neuroprotective compound verapamil, to mimic IA administration as a potential 
clinical therapeutic approach following endovascular thrombectomy. This was 
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done at a specific flow rate (2.5 µl/min) and injection volume (10 µl) to maximize 
ipsilateral hemispheric targeting of the agent of interest while minimizing 
systemic exposure (no significant effects were noted in heart rate and pulse 
distention between baseline measurements and the treated group post drug 
injection). This is an important result inasmuch as intravenous, systemically 
administered verapamil, an anti-hypertensive medication, would be expected to 
lower heart rate and pulse distention which can potentially cause bradycardia 
and hypotension by way of its venous return to the heart. Thereby further 
exacerbate stroke symptoms by decreasing post-recanalization cerebral blood 
flow and negating verapamil’s intended neurological effects. 
   Verapamil is routinely administered IA to the brain by 
neurointerventionalists to treat cerebral artery vasospasm after subarachnoid 
hemorrhage. Given its recognized safety profile in the clinical setting, along with 
speculation of its neuroprotective properties, we chose to study its potential as an 
adjunctive therapeutic in stroke models. While its proposed primary mechanism 
has been vasodilation of intracranial arteries, we propose that it may have direct 
neuroprotective effects through L-type calcium channels beyond the vascular 
bed. To address this question of mechanism, we examined perfusion using Laser 
Doppler (testing the focal MCA) and Laser Speckle (testing whole brain cortex 
perfusion). Following IA administration, the Laser Doppler showed transiently 
higher perfusion in the control group. However, overall, the administration of 
verapamil did not significantly affect perfusion whether focally in the MCA or 
globally for cortical perfusion in the short term. This contrasted with the control 
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group after drug administration that showed a significant drop in heart rate but a 
significant increase in perfusion units (blood pressure). Thus, the Laser Doppler 
and perfusion units correlate in the control group, showing an elevation relative to 
the verapamil treated group. Given the role in maintaining adequate cerebral 
perfusion in ischemic stroke, we would not expect an elevation in blood pressure 
after reperfusion to explain the highly significant difference between the control 
and treatment group. While reperfusion injury is a recognized issue after 
recanalization, the transient differences (relative tachycardia and lower pulse 
distention) seen in the treated group do not adequately explain the benefit of 
verapamil in neuroprotection. One limitation of this assessment was a lack of 
follow-up assessments in mice 12 - 24 hours after the procedure. Performing 
such an assessment would be challenging, but could provide additional data on 
the perfusion mechanisms for neuroprotection by verapamil in the setting of 
recanalized ischemic stroke.  
 Acute stroke therapies are aimed at preventing death and minimizing 
functional disability. In our experimental strokes, death rates were not 
significantly affected with treatment, but were universally low in all conditions 
(less than 5% in both groups), a particular advantage of this experimental stroke 
model over others. Functional outcome was measured using two behavioral 
tests, rotor rod for forced motor movement and open field for free roam to 
determine the effect of IA verapamil on post-stroke function. Similarly, in the 
open field testing, although both groups reduced their movement on PSD 1, the 
treated group improved by PSD 7, while the control group continued to decline. 
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Collectively, these results suggest that acutely-administered IA verapamil is very 
effective in preventing behavioral decline in experimental stroke. However, this 
experiment may be confounded on PSD 1 by the recent surgical procedure. 
Recovery can be seen when comparing naïve, treated and control PSD 1 rotor 
rod measurements to baseline measurements; we found variable rates of 
improvement from baseline for the naïve and control groups (23% and 0.86%, 
respectively) while the treated control group decreased (not significantly) 10% 
from baseline. However, such an effect should be dissipated by PSD 7. Finally, 
this analysis is somewhat limited by a lack of more long-term (> 30 day) 
functional assessment which is planned for future study. Therefore, the possibility 
that spontaneous functional recovery in the control stroked mice might eventually 
reach or plateau at the level of the stroked verapamil treated mice cannot be 
excluded. However, in the setting of our planned methods for gross and 
immunohistochemistry assessment, we feel that seven day post-stroke testing 
was reasonable for initial assessment of verapamil’s treatment effect.  
 Verapamil was further tested to determine its effect on brain tissue 
preservation. Brain TTC and immunohistochemistry showed a large reduction in 
infarct, with reduction in cellular apoptosis and preservation of mature neurons. 
We chose these experiments as markers of step-wise processing in ischemic 
stroke – ischemic volume, inflammatory cell activation and infiltration, cell death 
and apoptosis, and neuronal survival. In each case, our data supports the 
hypothesis that verapamil is neuroprotective on brain tissue when administered 
early and focally after reperfusion. Verapamil’s neuroprotective mechanism(s) of 
   
 
80 
 
action remain to be elucidated. Indeed, as it is clear from these experiments that 
verapamil has significant potential as a therapeutic adjunct to thrombectomy in 
ischemic stroke, further study is needed to focus on the mechanism by which 
verapamil acts in this setting as well as its efficacy in different clinical models of 
ischemia such as the embolic model.  
 Indeed, while there are a number of animal models to mimic stroke with 
their differing advantages and disadvantages, our model mimics distal M1/M2 
MCA vessel occlusion and produces the hallmark motor and physiological 
deficits one would expect to see in a patient presenting with an occlusion in the 
M1/M2 MCA. By comparison, injected thrombus models with t-PA have variable 
rates of recanalization, and technology does not exist to perform mechanical 
intracranial thrombectomy in a rodent model. While we do not inject a clot or 
administer t-PA in our ischemic stroke model, we are able to significantly 
decrease the flow of blood through the MCA as is seen clinically and un-occlude 
guaranteeing recanalization. For these reasons, we conclude that our 
experimental approach reasonably mimics selective IA neuroprotective 
administration after clinical ELVO thrombectomy.  
 Recent clinical trials such as MR CLEAN, ESCAPE, and EXTEND-IA have 
shown that endovascular thrombectomy is the new standard of care for ELVO 
stroke to ensure recanalization of the vessel and reperfusion of the ischemic area 
(12, 13, 60, 61). Incorporating IA administration of a potential neuroprotective 
agent following recanalization and reperfusion, would be a simple adjunctive 
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process, as the thrombectomy procedure inherently provides timely and selective 
arterial access to the cerebrovascular bed. While multiple neuroprotective agents 
have shown promise in animal studies, a lack of positive clinical data limited their 
adoption in patient care (15). These past studies did not have rapid access to 
selective arterial infusion after recanalization; our model provides this 
translational testing ground. Using our mouse model of acute ischemic stroke 
with IA administration we have shown verapamil is physiologically safe, improves 
functional outcome, decreases infarct volume, decreases astrogliosis activation, 
and increases mature neuron survival. The exact mechanism of these actions for 
verapamil is not yet known, and will be the focus of future studies that further 
elucidate additional efficacy for this drug and for neuropharmacology in ischemic 
stroke. However, this study provides the necessary data to support clinical 
evaluation of this therapy.  
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Chapter Five: Combinational Therapy 
Introduction 
 While IV t-PA and ET remain the gold standard for treatment of ELVO they 
are methods of recanalization and do not confer neuroprotection or neurorepair. 
Restoration of blood flow to the previously occluded area is the first step in 
treating ELVO. Even though recanalization rates have increased and times to 
recanalization have decreased, there has been a disconnect between 
recanalization rates and improved functional recovery. 
 Despite the fact that clinical trials looking at pharmacotherapy 
administration following stroke have largely failed, they have demonstrated the 
ability to target therapies at a specific receptor or signaling molecule. Using the 
IA model of drug administration we are looking to incorporate a two drug 
approach to target the acute and late phase of cellular degeneration following 
stroke. For the acute phase we selected verapamil, an L-type calcium channel 
blocker, due to its ability to regulate calcium influx in the early period of 
apoptosis. To treat later phases of apoptosis we selected lubeluzole, which 
regulates the NMDA receptors, to disrupt downstream glutamate. Administering 
two drugs with different mechanisms of action allows cells undergoing different 
phases of cellular degeneration to receive treatments specific to their level 
apoptosis.  
 Verapamil and lubeluzole were selected because of their preclinical and 
clinical history. Verapamil is used clinically to treat cerebral artery vasospasms 
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following successful recanalization but recently demonstrated in a preclinical 
setting to be neuroprotective when administered acutely following stroke. 
Lubeluzole also demonstrated neuroprotection in a preclinical setting but did not 
show benefit in clinical trials. While both drugs demonstrated neuroprotective 
effects in a preclinical setting, the same effect was not seen in the clinical model 
of ELVO. Here we present a method of combinational pharmacotherapy delivery 
that is clinically relevant but also addresses issues that might have caused both 
drugs to fail in clinical trials. First is successful recanalization because without 
restored flow the drugs will not be able to reach the target tissue. Second, we will 
administer one dose of each drug IA following successful recanalization since we 
feel a selective administration directly to the site of ischemia will provide a better 
outcome than broad dosing through IV. Our goal is to mitigate any systemic side 
effects while also ensuring the drug reaches the stroked tissue, verapamil if 
administered IV will cause vasodilation and could have significant effects on 
heart rate and blood pressure. Lubeluzole was serially delivered in the clinical 
setting but was halted because no effect was seen in mortality between 
treatment groups. By administering a one-time dose we are limiting the 
peripheral effects of the drugs but also enhancing their intended effects by 
selectively administering acutely.  
 Using the MCAo mouse model of stroke and IA pharmacotherapy delivery 
we tested a combinational therapy approach looking at overall neuronal health 
and functional outcome. Here we present the methods and results outlining our 
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case for why a combinational therapy approach for stroke treatment is safe and 
effective. 
Material and Methods 
 Experiments conformed to protocols and guidelines set forth by the 
University of Kentucky Division of Laboratory Animal Research, Institutional 
Animal Use and Care Committee and ARRIVE Guidelines (83). In brief, 16 week 
old C57/Bl6 (25 - 30 gram) male mice from Jackson Laboratories were separated 
into 3 groups (control, treated and naïve) in a blinded fashion using randomized 
selection. Groups were divided into naïve (age matched litter mate controls), 
control (MCAo surgery with 10 µl saline (APP Pharmaceuticals) injected at 2.5 
µl/min IA), and treated (MCAo surgery with 10 µl + verapamil/lubeluzole injected 
IA). Verapamil (Hospira) was administered at a dose of 0.15 milligram (mg) per 
kilogram (kg) and lubeluzole (Sigma Aldrich) was administered at a dose of 0.63 
mg per kg (49, 50, 81, 82). Doses were extrapolated from both preclinical and 
clinical doses using an intravenous/intraperitoneal method of drug delivery. 
Previous studies for flow rate and injection volume allowed us to determine the 
optimal flow rate of 2.5 µl/min with an injection volume of 10 µl per mouse (36, 
63). Perfusion measurements, physiological measurements, behavioral 
measurements, infarct volume and immunohistochemistry were conducted in a 
blinded fashion. Exclusion criteria was applied to any animal that had a ruptured 
MCA or CCA during MCAo surgery, died during the study, or was shown to have 
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poor health and was euthanized due to study protocol. Our MCAo and IA model 
had a death rate of <5% in both surgery and behavior.   
Animal Number 
 We conducted the experiment with a sample size of 23 animals; 12 (7 
treated and 5 control) were used for perfusion measurements and physiological 
measurements, 11 (5 treated, 3 control) behavioral assessment (historical 
controls included), infarct volume and immunohistochemistry. Groups were 
divided into naïve, control and treated.  
Perfusion 
 Blood flow through the MCA was measured at baseline and occlusion 
using a Laser Doppler Periflux System with a 2 mm tip (Perimed).  
Physiological Measurements 
  Vital signs were monitored with the MouseOx Plus (Starr Life Science). To 
monitor pulse distention (blood pressure) and heart rate a thigh sensor was 
placed over a shaved section of the left thigh. Measurements were taken at 
baseline (0 – 5 minutes), reperfusion/drug administration (5 minutes post 
reperfusion) and post drug administration (10 and 15 minutes reperfusion).  
MCAo and IA injection 
 Animals were anesthetized using a weight based ratio of Ketamine and 
Xylazine mixture for both the MCAo and IA procedures. Induction of focal 
cerebral ischemia through the MCAo model was induced using our previously 
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described method (36, 37, 63). MCAo was for one hour with baseline and 
occlusion confirmed with Laser Doppler, previous studies have demonstrated a 
60% recanalization at 15 minutes post occlusion (36, 63). Animal body 
temperature was maintained on a heating pad throughout MCAo and IA 
procedure, to ensure the core body temperature did not drop below 
recommended levels a rectal thermometer was attached to the MouseOx Plus. 
Post MCAo and IA procedure, animals were moved to a heated recovery cage 
and checked at 5 minute intervals until fully awake and able to be returned to the 
animal facility.  
 Intra-arterial injection of combinational drug or saline followed our 
previously published protocol (36, 63). In short, during the MCAo occlusion we 
further exposed the CCA superiorly until reaching the bifurcation into the ICA and 
ECA. The ICA and ECA are exposed allowing for distal permanent occlusion of 
the ECA and temporary occlusion of the ICA, a small nick was made midway 
between the proximal and distal end of the ECA. Micro-angio tubing was placed 
into the ECA and threaded until it reached the bifurcation and secured with 
temporary suture. Following the one hour occlusion the CCA and ICA clamp as 
well as the MCA metal wire filament were removed restoring blood flow to the 
cerebrovasculature. After five minutes of recanalization a syringe pump injected 
the study agent (combinational drug or saline) over a period of four minutes at 
the previously described flow rate and injection volume. Once the injection was 
complete the ECA was suture ligated at the proximal end (closest to the CCA 
bifurcation) and the temporal and cervical region was sutured.  
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Behavioral Testing 
 Animals underwent two behavioral tests, rotor rod for forced motor 
movement and open field for free roam, to determine functional outcome after 
MCAo and IA pharmacotherapy administration. For rotor rod, animals were 
grouped, naïve (age matched litter mate controls), treated (MCAo surgery with IA 
injection of verapamil/lubeluzole), and control (MCAo surgery with IA saline 
injection). Training occurred three days prior to MCAo and baseline 
measurements were taken one day prior to MCAo, and tested three days 
following stroke surgery, post-stroke day 1, 3 and 7. Rotor rod consisted of three 
trials with mice being placed on a rotating rod for five minutes with increasing 
acceleration from 0 - 40 rpm. Measurements are reported as percent change 
from baseline for individual animals and grouped together. Open field contained 
the same groups and consists of four squared boxes (50 cm by 50 cm by 30 cm) 
with an top down mounted infrared camera to track animal movement. Open field 
parameters were set to measure percent change from baseline. Measurements 
were taken at baseline (day prior to MCAo) and PSD 1 and 7. 
Infarct Volume 
 Mice were euthanized on PSD 7 via cervical dislocation and whole brains 
removed, flash frozen, sectioned on a cryostat (20 µm) and stained using cresyl 
violet. Infarct volume analysis from scanned cresyl violet images was analyzed 
using NIH Image J software (36, 37, 63).  
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Immunohistochemistry 
 Whole flash frozen brains were sectioned on a Leica CM 1950 cryostat at 
20 µm and mounted. NeuN (1:500 antibody dilution, Abcam) 
immunohistochemistry was used to measure mature neuron survival in the 
stroked region (penumbra and core). Glial Fibrillary Activating Protein (GFAP 
1:500 antibody dilution, Sigma) immunohistochemistry was used to assess 
astrogliosis. Infarct corresponds to the core and penumbra in the cortex or the 
epicenter of the stroke affected region, morphologically identified to include the 
greatest area. Fluorescent stains were visualized using a Nikon Eclipse Ti 
microscope at 20X magnification with images collected using an attached CCD 
camera to a dedicated computer and quantified with Adobe Photoshop. 
Sectioned brains from sham, treated and control were analyzed using Nikon NIS 
Element BR Analysis imaging software. Brains were sectioned and plated four 
slices to a slide with a total of 40 slices over 10 slides.  
Statistical analysis 
 All measured variables are shown as ± Standard Error of the Mean (SEM). 
For comparison between treatment groups (infarct volume, 
immunohistochemistry) a Student’s t-test was used for analysis. Time course 
comparisons (physiological measurements, behavior) were analyzed using a 
Two-way repeated measures ANOVA. Significance was defined as * P ≤ 0.05, ** 
P ≤ 0.01, and *** P ≤ 0.001.  
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Compliance with STAIR 
 Study design was implemented with reference to STAIR recommendations 
for preclinical neuroprotection trials and to maximize the applicability of our 
results. Drug doses were selected on previously published preclinical and clinical 
data currently used by neurointerventionalists to treat patients in the angiography 
suite (49, 50, 81, 82). To better determine optimal and deleterious doses a future 
dose response study has been planned. To best mimic the clinical condition, 
drug administration followed successful recanalization (five minutes post) to 
maximize the window of opportunity for each drugs targeted effects. The study 
was conducted in a blinded fashion with drug treatment randomized. A power 
analysis was conducted to confirm adequate number of subjects per group. For 
safety we monitored animal’s vital signs (pulse distention and heart rate) but also 
demonstrated a 77% reduction of blood flow through the MCA as stated in the 
results section. Drug effect following MCAo, successful recanalization and IA 
injection was evaluated using infarct volume, behavior and 
immunohistochemistry. Future studies are planned to determine differences in 
gender and age.  
Results 
Perfusion 
 Laser Doppler perfusion measurements were taken at baseline 
(anesthetized animal, no surgery) and after MCAo (MCA and CCA occluded) 
induction. Laser Doppler perfusion measurements from baseline (265.75 ± 
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16.23) to occlusion (60.22 ± 5.09) demonstrated a 77% reduction in flow through 
the MCA (Figure 5.1).  
Physiological Measurements 
 Baseline heart rate (beats per minute, bpm) measurements for control and 
treated groups (Figure 5.2A), measurements were combined prior to MCAo and 
drug injection at zero minutes (227.03 ± 2.92) and five minutes (210.17 ± 8.08), 
showed a non-significant decrease of 17 bpm over a five minute period. At 
reperfusion (following MCAo and successful recanalization) the heart rate for 
combined groups decreased significantly (147.78 ± 0.15) from baseline. At drug 
administration both treated (144.29 ± 0.15) and control (147.33 ± 0.01) remained 
significantly decreased from baseline (five minutes) but not from each other. Post 
15 minutes drug administration both treated (149.55 ± 0.22) and control (149.67 
± 0.06) remained significantly reduced from baseline (five minutes) but no 
different from reperfusion or drug administration against each other. 
 Pulse distention (blood pressure) baseline measurements (Figure 5.2B) 
for control and treated groups were combined at zero minutes (34.27 ± 0.23) and 
five minutes (32.34 ± 0.61), showed a non-significant decrease of 1.93 µm over 
five minutes. Following reperfusion pulse distention decreased for combined 
groups (28.40 ± 0.06) 3.94 µm from baseline (five minutes). Groups separated at 
drug administration with treated increasing (35.99 ± 0.15) from both baseline and 
control, control decreased (27.06 ± 0.03), neither group was significantly different 
from baseline (five minutes). Post 15 minutes drug administration, the treated  
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INTRA-ARTERIAL COMBINATIONAL THERAPY PERFUSION 
 MEASUREMENTS  
 
  
Figure 5.1. Laser Doppler blood perfusion through 
middle cerebral artery Pre and Post occlusion, 
reduction for combined groups. Reduction of 78%. (n 
= 37)  
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INTRA-ARTERIAL COMBINATIONAL THERAPY PHYSIOLOGICAL 
MEASUREMENTS  
Figure 5.2. MouseOx Plus Physiological Measurements for 
Combined (black), Treated (red) and Control (blue) groups., A. 
Heart rate in beats per minute (bpm), 0 - 5 minutes (baseline 
measurements), 65 minutes (reperfusion/un-occlusion and drug 
administration), 70 and 75 minutes (reperfusion)., B. Pulse 
Distention measuring vessel diameter (micrometer or µm), 0 - 5 
minutes (baseline), 65 minutes (reperfusion/un-occlusion and 
drug administration), 70 and 75 minutes (reperfusion), Combined 
(n = 36), Control (n = 5), Treated (n = 5) 
A 
B 
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group remained elevated (34.44 ± 0.15) from baseline but the control (27.61 ± 
0.03) remained decreased from baseline and treated.  
Behavioral Testing 
 Animals were tested using forced motor (rotor rod) movement (Figure 
5.3A) measured in percent change from baseline, groups were trained for three 
days and tested for baseline measurements one day prior to stroke. Following 
stroke and IA drug treatment administration on post-stroke day (PSD) 1, the 
control (-0.95 ± 11.86) and treated (-3.61 ± 19.90) showed no difference between 
groups. However on PSD 3 the groups separated, with treated (31.24 ± 10.08) 
being significantly different (P < 0.01) from control (-31.20 ± 14.07). The trend 
continued on PSD 7 with the treated group (34.69 ± 13.65) again being 
significantly different (P < 0.001) from control (-54.78 ± 29.31). Naïve treated 
animals showed improvement (not significant) on PSD 1 (23.71 ± 5.48) 
compared to treated and control. The naïve group continued to improve on PSD 
3 (25.31 ± 12.51) and was significantly (P < 0.01) from control but not treated, a 
trend which continued on PSD 7 (29.31 ± 19.51) (P < 0.001).  
 Animals were again tested using free roam (open field) movement (Figure 
5.3B) with percent change from baseline measured over a five minutes, both 
groups significantly (P < 0.001) decreased from baseline on PSD 1 (control -
129.00 ± 27.21 vs. treated -181.73 ± 39.53) but were not different from each 
other. On PSD 7 the treated group (-65.18 ± 11.20) and control group (-109.83 ± 
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14.90) both improved but not significantly from each other (P < 0.055). The naïve 
group at both PSD 1 (9.01 ± 3.75) and PSD 7 (-33.17 ± 10.18) was significantly 
(P < 0.001 and P < 0.01)) improved from both treated and control.  
Infarct Volume 
 Analysis of infarct volume (Figure 5.4A) was assessed from cresyl violet 
staining (Figure 19B) on PSD 7 with Image J. Infarct volumes (mm3) are 
significantly different (P ≤ 0.009) between control (21.94 ± 5.26) and treated 
(4.54 ± 1.91).  
Immunohistochemistry 
 Antibodies specific to proteins associated with mature neuron survival 
(NeuN) and astrocytic inflammation/infiltration (GFAP) were used (Figure 5.5 A – 
F). Compared to control, combinational therapy treated animals showed a 
significant (P < 0.001) increase in NeuN positive pixel density. Similarly, 
combinational therapy treated animals had a significant (P < 0.001) decrease in 
GFAP positive pixel density compared to control.  
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INTRA-ARTERIAL COMBINATIONAL THERAPY BEHAVIORAL 
MEASUREMENTS 
  
A 
# 
&& 
&& 
B 
### 
# 
Figure 5.3. Behavioral measurements for Rotor Rod and Open 
Field for Treated (red), Control (blue) and Naïve (gray)., A. Rotor 
Rod forced motor movement test for percent change from 
baseline, groups separated on post-stroke day (PSD) 1 into 
treated, control and naïve and were tested on PSD 1, 3 and 7., B. 
Open Field free roam movement separated into treated, control 
and naïve and were tested on PSD 1 and 7. Rotor Rod: Treated 
(n = 5), Control (n = 23) and Naïve (n = 4), Open Field: Treated (n 
= 5), Control (n = 16) and Naïve (n = 4). # indicates P < 0.05 for 
naïve versus treated/control, ### indicates P < 0.001 for naïve 
versus treated/control, && indicates P < 0.001 for treated/naïve 
versus control.  
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Figure 5.4. A. Infarct volume analysis for control versus treated using TTC and cresyl violet 
stained stroked tissue. Control (n = 6) Treated (n = 6)., B. TTC Image for control group., C. 
TTC image for treated group.  
Control Treated 
A B C 
INTRA-ARTERIAL COMBINATIONAL THERAPY INFARCT VOLUME ANALYSIS  
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Figure 5.5. Graphs and images for immunohistochemistry magnification at 20X with quantification of 
positive pixel density. A. Graph depicting positive pixel for NeuN stain of control versus treated in infarcted 
region., B. Image of control NeuN stain from infarcted region at magnification 20X., C. Image of treated 
NeuN stain from infarcted region at magnification 20X., D. Graph depicting positive pixel for GFAP stain of 
control versus treated in infarcted region., E. Image of control GFAP stain from infarcted region at 20X., F. 
Image of treated GFAP stain from infarcted region at magnification 20X.,Control (n = 6), and Treated (n = 
6) White scale bar, 100µm. ** indicates P < 0.001 
A 
D 
E 
B C 
F 
Control Treated 
INTRA-ARTERIAL COMBINATIONAL THERAPY IMMUNOHISTOCHEMISTRY 
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Discussion 
 Stroke continues to affect millions of individuals annually and with the 
incidence expected to double by 2050 the need for new therapies is vital. Current 
therapies of IV t-PA and ET offer improved recanalization rates but this does not 
correlate with improved functional outcomes. Adjunctive therapies to be used 
following successful recanalization targeted at specific cellular pathways will 
assist in preserving neuronal tissue. While a number of pre-clinical trials 
demonstrated positive effects following animal models of stroke, the transition to 
the clinical practice did not show the same success. We feel the breakdown 
between pre-clinical and clinical stroke trials can be attributed to a few key areas; 
(1) successful recanalization of the previously occluded vessel, (2) administering 
potential neuroprotective drugs in a representative time frame that will allow the 
drug to affect the targeted pathway, (3) selective administration, guaranteeing the 
drugs reach the ischemic tissue by selectively administering directly to the site of 
occlusion.  
 Using a clinically relevant mouse model of stroke we incorporated the 
above factors of successful recanalization, timely drug delivery and targeted 
administration to test a combinational therapy approach. We selected verapamil 
and lubeluzole as our neuroprotective agents, both are FDA-approved and have 
shown pre-clinical and clinical neuroprotection. Verapamil is an L-type calcium 
channel blocker currently used for cerebral artery vasospasms but in a recent 
pre-clinical study demonstrated neuroprotective benefits. Lubeluzole is an NMDA 
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modulator and successfully completed a number of pre-clinical studies before 
being halted in clinical trials. Our goal is to select a combination of drugs that can 
be used to activate or downregulate specific cellular pathway’s during and 
following stroke. Because the infarcted tissue is undergoing different stages of 
apoptosis the ability for one drug to treat multiple pathways is unlikely. We will 
administer our drugs IA following successful recanalization to target the acute 
and delayed phases of cellular apoptosis. Verapamil will be used for the acute 
phase when cells undergo a membrane depolarization and allow L-type calcium 
channels to open increasing the amount of calcium intracellularly. Lubeluzole will 
be used for the delayed phase, after cells have undergone a membrane 
depolarization and an intracellular cascade is triggered. We hope to regulate 
NMDA receptors and glutamate release intracellularly, by doing so we will inhibit 
the lipid peroxidation and DNA degeneration that are directly related to increased 
intracellular glutamate. 
 To determine if our combinational therapy was effective we looked at a 
variety of measures to determine drug safety and efficacy both functionally and 
histologically. First we determined whether our drug combination had an effect on 
physiological measurements (heart rate and pulse distention), we showed no 
difference in heart rate between controls and treated following recanalization, 
drug administration and reperfusion. Next we looked at pulse distention (blood 
pressure) and found the treated group returned to baseline measures following 
drug administration and reperfusion but the control group remained significantly 
lower than both baseline and treated. To determine if there was a functional 
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difference we tested our groups on rotor rod (forced motor movement) and open 
field (free roam movement) and found in both tests that the treated group 
improved but it was significant in the rotor rod and trending towards (P < 0.055) 
significance in the open field.  
 Following a successful functional test we looked at infarct volumes 
between treated versus control, and found the treated group to have a 
significantly (P < 0.05) lower infarct volume (mm3) than the control group. The 
reduction in infarct volume correlates well with the improved functional outcome 
at later time points (PSD 7) in the treated group. 
 Lastly we looked at histological measures of neuronal health and 
astrogliosis; in both measures we found the treated group to have significant 
improvement over the control group. Looking at neuronal health, we used NeuN 
to measure the amount of healthy neurons in the infarcted and penumbral region 
and found a greater percentage of healthy neurons in treated compared to 
control. This could be attributed to the acute and delayed drug treatment of 
verapamil and lubeluzole, by targeting early calcium channels and NMDA 
receptors, we are selectively treating specific cellular cascades. Next we looked 
at astrogliosis or the infiltration/activation of astrocytes, the control group which 
received IA saline had a greater number of astrocytes in the infarcted/core region 
than the treated groups. A decrease in astrogliosis correlates with decreased 
infarct volumes and insults to the brain, again we targeted an early and late stage 
therapy that has demonstrated positive results. 
   
 
101 
 
 As a whole, a combinational approach post stroke allows for a greater 
opportunity to treat tissue of varying degrees of cellular death. Starting from the 
core (area closest to occluded vessel) and spreading to the penumbra (area 
receiving watershed blood flow), the amount of degradation is highest in the core 
and decreases as it radiates outward. The advantage of a combinational 
approach allows for cells in the core and penumbra to receive treatment at their 
specific stage of cellular degeneration and halt further damage allowing the cells 
to begin reparative processes. A two drug approach allows for a more broad 
therapeutic approach, and demonstrates a neuroprotective benefit in both a 
functional and histological approach. Results from this study while positive 
should be applied to female mice, aged mice and used under different models of 
stroke to fulfill the STAIR criteria.   
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Chapter Six: General Discussion 
 Worldwide stroke remains a leading cause of mortality and long-term 
morbidity; with an aging population, the number of individuals suffering a stroke 
is expected to double by 2050 (1-3). Ischemic stroke (>80% of strokes) occurs 
when blood flow to the brain is occluded by a clot, which typically occurs within 
the large vessels of the brain. A subset of ischemic stroke, emergent large vessel 
occlusion (ELVO) is the most disabling and life-threatening form of ischemic 
stroke. To date, the only FDA-approved pharmacotherapy for ischemic stroke is 
intravenous (IV) tissue plasminogen activator (t-PA), but due to extensive 
exclusion criteria, relatively few are eligible (3). The mechanism of action for IV t-
PA is to break down a clot through a series of chemical reactions. While this 
process restores blood flow to the previously occluded portion of the brain it does 
not confer neuroprotective or neuroreparative benefits. Without a steady blood 
flow, the brain and more specifically the neurovascular unit under goes a hypoxic 
(lack of oxygen and nutrients) event leading to cellular death. This cellular death 
is triggered by, the intrinsic/mitochondrial apoptotic pathway, causing a cascade 
of cellular signals both extracellular and intracellular. The intrinsic pathway 
begins with an insult leading to membrane depolarization and cellular membrane 
channels opening causing an increase in chemical transport across the cell 
membrane disturbing the balance between intra- and extracellular environments. 
This imbalance can be restored if aid is rendered before the cell reaches a point 
of no return; up until this point the ability of administering therapy and restoring 
proper cellular function remains possible.  
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 To date, there are only two approved therapies for ELVO, IV t-PA and 
endovascular thrombectomy (ET), and while both have improved recanalization 
rates, there is disconnection with positive functional outcome (12). An adjunctive 
therapy following successful recanalization that targets cell-specific pathways in 
the neurovascular unit could improve outcome. Drugs conferring neuroprotective 
benefits have performed well in pre-clinical testing, but there is currently no 
pharmacotherapy option (t-PA aside) that has successfully transitioned from the 
pre-clinical models to the clinic; as all failed to demonstrate positive effects 
following stroke. This highlights a disconnection between the bench and the 
bedside, and can be attributed to a number of causes. Previous pre-clinical and 
clinical trials demonstrated a deficiency in experimental design evaluating 
heterogeneous stroke patients, a lack of co-administration of neuroprotectants 
with thrombolytics, delay in drug initiation up to 48 hours, and an in ability to 
ensure that the treatment agent reached ischemic tissue (15).  
 Endovascular thrombectomy uses a catheter threaded through the 
patient’s vasculature to mechanically remove a clot restoring blood flow, but it 
also allows for targeted pharmacotherapy treatment directly to the site of 
ischemia following recanalization. Delivering a drug selectively has many 
advantages: lower concentration of drug is needed, systemic side effects can be 
minimized, the agent can be directly given to the pathological tissue, and it can 
piggyback on an approved therapy (ET).   
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 While there are a number of mouse models of stroke, the tandem transient 
common carotid/middle cerebral artery occlusion (MCAo) model is representative 
of large vessel occlusion. This model mimics ELVO in that it guarantees 
successful recanalization, generates a cortical infarct similar to the clinical 
condition and allows for a catheter to be threaded into the cervical vasculature to 
intra-arterially deliver pharmacotherapy (20, 36, 37, 63). Using the already 
exposed cervical vasculature of the MCAo model, the CCA is isolated superiorly 
until the CCA bifurcation is reached and the ECA and ICA exposed. Micro-angio 
tubing was inserted into the ECA toward the ICA and a series of carbon black 
dye injections were administered to optimize the flow rate and injection volume. 
Working from max needle flow and syringe volume we were able to determine 
the optimal flow rate to be 2.5 μl/min with an injection volume of 10 μl. The use of 
carbon black ink allowed us to determine staining throughout the brain and 
systemic circulation and help narrow the optimal range. Though carbon black ink 
has a greater density than potential neuroprotective compounds (typically 
dissolved in saline) it provides a starting point that will allow future studies to test 
potential neuroprotective compounds.  
 Translational projects strive to mimic the clinical condition; our model of IA 
administration allows us to bypass threading a catheter from the femoral artery of 
a mouse but limits us to administering the drug into the ICA and not directly into 
the MCA. If the micro-angio tubing was to be threaded into the ICA and MCA it 
would occlude the recanalized CCA and ICA during injection. This would hinder 
the injected drug from being carried by the blood to the ischemic tissue. By 
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injecting into the ICA directly we are using the recanalized blood vessel to carry 
our agent of choice to the target region. Carbon black staining demonstrated that 
even when injecting into the ICA and not directly into the MCA we are able to 
reach the ischemic tissue while not hindering the recanalized vessel or 
overshooting our target region.  
 Improvements of the model would be smaller tubing threaded into the ICA 
to the MCA without significantly hindering flow, to date the needle gauge and 
tubing diameter (internal bore and external diameter) needed are not available. If 
the IA model were used in a larger animal model (rabbit or dog) the current 
needle and tubing setup would allow for more direct administration to the MCA. 
This would require optimization as the flow rate through a larger animal’s 
vasculature will be different than a mouse. STAIR criteria recommends testing a 
method in different models and animal species.  
Intra-arterial Model 
 The IA model will work in most stroke models but caution must be used in 
the suture model (MCAO) as it uses the same vasculature to thread the suture 
and occlude as we use to thread our catheter. The ability to transition between a 
suture and catheter following MCAO without significant blood loss is major factor. 
The IA model would work well in the thrombin/embolic clot model as it could be 
used to administer IA t-PA in smaller doses directly to the occluded vessel and 
mimic ELVO and ET. The photothrombotic model would not be a good stroke 
model as it is a permanent occlusion and recanalization and IA administration to 
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the site of ischemia cannot be achieved. Overall the IA model will work in a 
number of stroke models and could be scaled up to larger animal species but first 
optimization of flow rate and injection volume is needed.  
Nitroglycerin 
 A potential neuroprotective compound, nitroglycerin or glyceryl trinitrate 
(GTN) is a known vasodilator used in clinic to treat angina and other heart 
conditions. Starting in the early 2000's, GTN was evaluated clinically as a 
potential therapy for stroke, applying a GTN patch for seven days to an individual 
suffering stroke following recanalization (41, 43, 84). The hypothesis behind 
applying the patch was a decrease in systemic blood pressure would relate to 
neuroprotection and better functional scores at 90 days post stroke. The recently 
published ENOS trial showed an acute reduction in blood pressure following 
patch placement but no significant difference between treated and control groups 
at 90 days post-stroke (41, 43). The primary objective of improved functional 
outcome (shifting the Modified Rankin Scale-clinical measure of functional stroke 
assessment) was not met but a reduction in acute blood pressure was achieved. 
Reducing blood pressure during and following stroke will help decrease the 
chance an individual will suffer increased ICP, a common symptom. While 
improved functional outcome was not met overall, a sub analysis of ENOS 
patients receiving a GTN patch within six hours had a beneficial shift in functional 
outcome and reduced death (84). Though GTN is a known vasodilator it also has 
a proposed secondary mechanism of action as a nitric oxide (NOx) donor. Nitric 
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oxide has been shown to reduce inflammation, maintain vascular tone and 
reduce infarct volume (anti-apoptotic) (74). GTN is converted to NOx through a 
series of reactions following its uptake into the vascular endothelium and 
released into the blood stream where it works on smooth muscles surrounding 
the vessel and directly on neurons through inhibition of nitric oxide synthase 
(NOS).   
 Similar to verapamil being used to treat cerebral artery vasospasms, GTN 
is used following ET to open collapsed cortical vessels following recanalization. 
GTN's neuroprotective potential following ELVO and ET was tested in our 
preclinical MCAo and IA model to determine if it had protective benefits. As with 
verapamil, most believe any beneficial effect will come from restored/increased 
blood flow to the brain. Because there is no known IA dose of GTN, five doses 
were selected to test for safety (physiological measurements) and from those 
doses three were selected (3.1, 6.2 and 12.5 μg/μl) for treatment. Using the 
Laser Doppler, MCA perfusion measurements following recanalization and GTN 
administration were taken. There was no significant difference between GTN 
treatment and vehicle groups. Nitroglycerin groups did show a dose dependent 
increase in perfusion with the 3.1 μg/μl having the highest perfusion and the 12.5 
μg/μl having the lowest. This is contrary to what was expected, and possible 
reasons are: (1) higher doses of GTN are more concentrated upon IA injection 
and will saturate the ICA endothelium whereas lower IA GTN doses are diluted 
and will work transiently throughout the ICA and MCA, (2) GTN is converted into 
NOx and released back into the blood stream, (3) we missed the full effect of 
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GTN (half-life of 2.5 - 7.5 minutes) by measuring outside its effective range 
(started measuring 10 minutes post-IA injection). 
 As with all potential neuroprotective compounds, the primary outcome 
measure is improved functional recovery over time. GTN was administered 
following MCAo and successful recanalization with mice being tested using 
forced motor movement over seven days (PSD 1, 3 and 7) and compared to 
baseline (day prior to stroke). Similar to perfusion measurements, lower doses of 
GTN (3.1 and 6.2 μg/μl) had an acute effect with significant improvement on PSD 
1 compared to control but this effect dissipated on PSD 7 with both groups 
beginning to decline. The acute effect seen in lower doses could be from 
increased blood flow and a transient increase of NOx production helping spare 
neurons in the motor cortex region. The effect dissipates over time as neurons 
farther from the treatment site (penumbra) which did not receive NOx continue 
through cellular degeneration leading to decreased functional ability over time. 
The 12.5 μg/μl group decreased from baseline on PSD 1 but significantly 
improved by PSD 7, overall the higher dose of GTN improved during the test but 
had variability initially. This effect could be related to greater NOx production, as 
GTN is administered IA it is converted into NOx and circulates through the 
ischemic region. Circulating NOx will be taken up by neurons in the ischemic 
region undergoing apoptosis and block NOS, hindering further cellular 
degradation. This effect can be seen in improved functional movement from PSD 
1 to 7. Nitric oxide may preserve neurons in the motor cortex and as they begin 
to recover so will the functional outcome.  
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 Increased blood NOx levels (12.5 μg/μl) were confirmed through blood 
draws 15 minutes post stroke and on PSD 1 compared to baseline (day prior to 
stroke). While the effect on both time points was not significantly different than 
control, NOx levels did show an elevation beyond normal levels following stroke. 
Previous studies have shown that NOx levels are acutely elevated (30 minutes) 
following stroke and drop below baseline during subsequent days (74). This 
increase in NOx levels beyond physiological normal measurements might be the 
reason GTN treated mice performed better compared to control (all doses) in the 
rotor rod. While NOx is increased following stroke, GTN's conversion to NOx will 
boost the concentration of NOx levels available. Increased circulating NOx will 
increase vascular tone, decrease inflammation and work through anti-apoptotic 
mechanisms to preserve neuronal health in the infarcted region.    
 Lastly we looked at histological measures of mature neuron survival and 
astrogliosis in the infarcted region and found a stair step dose response effect. 
Mature neuron survival was observed least at dose 3.1 µg/µl and greatest with 
the 12.5 µg/µl dose. The opposite trend was seen in astrogliosis with the 3.1 
µg/µl having the greatest expression and the 12.5 µg/µl dose having the lowest. 
The two trends correlate, fewer neurons dying leads to less astrocyte 
infiltration/activaton to clean up and support the infarcted region. As was seen in 
infarct volume, IA GTN works in a dose escalating fashion showing protective 
effects at higher doses. The preservation of neurons in the infarcted region can 
be attributed to a return of nutrient rich blood and NOx, both provide key 
components a neuron needs to survive. NOx will work to preserve neuronal 
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health by stopping the apoptotic cascade and the return of glucose will allow the 
cell to resume energy production. With fewer neurons dying, the need for 
astrocytes to infiltrate and support/clean up cellular debris is lessened.  
 The use of GTN as a neuroprotective compound has demonstrated 
positive effects in a sub analysis of ENOS, but the primary measure of better 
functional outcome was not met for the main study. This could be related to GTN 
patch application over a period of seven days and having greater systemic 
effects than targeted effects in the cerebrovasculature. While ENOS did show an 
acute reduction in blood pressure this was not enough to alter 90 day functional 
scores between groups. Using GTN in our model of IA administration, it was 
shown to be physiologically safe, have little effect on vessel dilation, have a 
functional effect, decrease infarct volume and preserve neuronal health. These 
positive results are attributed to successful recanalization of the occluded vessel 
and conversion of GTN to NOx. Neuroprotection is two-sided, neuroprotective 
drugs are beneficial to stopping cellular cascades associated with apoptosis, but 
a neuron needs nutrients to continue energy production. Working together, 
recanalization and IA GTN demonstrated neuroprotective effects following ELVO. 
Verapamil 
 Verapamil has a long history in cerebrovascular disease but is not 
currently used for stroke treatment. It is administered following successful 
recanalization when a previously occluded MCA vessel wall spasms causing 
turbid blood flow through the cerebrovasculature. Verapamil was selected 
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because it is FDA-approved, currently used in the clinic, and at one time was 
suspected of having neuroprotective benefits. Previous pre-clinical stroke 
experiments testing verapamil suffered from experimental study design flaws; 
most notable is not successfully recanalizing the occluded vessel and delayed 
drug administration (44-46). Verapamil has two proposed mechanism of actions, 
first, blocking L-type calcium channels on the cell membrane, and second, 
vasodilation of the blood vessel through blocking calcium release and smooth 
muscle relaxation. It is noteworthy that verapamil is used outside of the 
neuroprotection field to block p-glycoprotein pumps (PGP), thereby inhibiting the 
efflux of target species from intracellular to extracellular.  
 Using the MCAo and IA models, we tested verapamil for safety and 
neuroprotective benefit and to determine if the protection was from vasodilation 
or blocking of L-type calcium channels. Administration of vasodilators can cause 
a decrease in heart rate (decreased muscle contractions) and drop in blood 
pressure (vessel dilation). Following stroke, a series of physiological responses 
known as Cushing's triad (increased intracranial pressure-ICP, decreased blood 
pressure and increased heart rate) can occur causing a worse outcome. Making 
sure potential neuroprotective agent(s) do not exacerbate these symptoms is 
key. Verapamil administered IA following successful recanalization demonstrated 
a heart rate similar to baseline and lowered blood pressure (not significant), while 
the control group (IA saline) had an increased pulse distention (blood pressure) 
and lowered heart rate 10 - 15 minutes post drug administration. Physiological 
measurements demonstrate that verapamil preserved heart rate and pulse 
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distention following MCAo but the control group demonstrated 2/3 of Cushing's 
triad which could mean the mouse suffered increased ICP following 
recanalization.  
 To dispel the myth that verapamil's neuroprotective effect is through 
vasodilation we looked at two measures of vessel dilation, global and local. Laser 
Doppler was used to measure perfusion through the ipsilateral MCA and Laser 
Speckle was used to measure hemispheric flow comparing contralateral versus 
ipsilateral. Results from Laser Doppler and Speckle show there is no difference 
in perfusion through either the ipsilateral MCA or ipsilateral hemisphere when 
compared to contralateral. Laser Doppler showed greater flow (not significant) for 
IA control through the MCA at drug administration, 10 and 15 minutes post 
administration compared to IA verapamil. Laser Speckle demonstrated an 
increased (not significant) return to global perfusion (contralateral versus 
ipsilateral perfusion measurements) for IA verapamil versus IA control. Here we 
dispel the notion that verapamil's main mechanism of action is vasodilation, and 
while some effect can be observed, it is not significant between groups. This can 
be attributed to blood vessels of the brain already being maximally dilated, trying 
to return blood supply to the effected region. This could be tested by looking at a 
known vasodilators such as nitroglycerin and measuring cerebrovascular 
perfusion both locally and globally. 
 In the clinic, the goal for stroke patients is to return to normal function or 
return to functional ability one day prior to stroke. To test whether verapamil 
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conveyed neuroprotective benefits, mice were tested on the rotor rod (forced 
motor movement) and open field (free roam movement) on specific days. The 
reasoning behind the functional test lies in the MCAo model, because the MCA 
supplies blood to the motor cortex of the brain responsible for forelimb 
movement. Occluding the MCA should produce a functional deficit on the 
contralateral forelimb making forward mobility difficult. Both behavioral tests 
showed the control group having decreased mobility on testing days (open field 
PSD 1 saw no difference between groups) when compared to verapamil treated. 
The difference in functional performance with the treated group performing better 
than control would lend support to the theory that verapamil was protective of the 
neurons in the motor cortex of the brain, thus allowing for better control and 
movement of the forelimb.  
 Next, we examined infarct volume to determine if there was any difference 
between groups. Infarct analysis showed the treated group had a significantly 
smaller infarct than the control meaning verapamil conveyed a protective effect. 
While the decrease in infarct correlates to improved functional outcome, it was 
the histological data that helps support verapamil's claim as neuroprotective.  
 Histologically, groups were stained looking at mature neuron survival, 
astrogliosis, and apoptosis. Neurons cannot produce glucose and require nutrient 
rich blood for a continuous supply. If glucose is deficient, mitochondria in the cell 
will no longer make adenosine tri-phosphate (ATP) causing a breakdown in 
cellular function leading cellular degeneration. The mitochondrial or intrinsic 
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pathway of apoptosis begins with membrane depolarization leading to the 
opening of L-type calcium channels on the cellular membrane surface. This 
opening leads to calcium influx and eventual imbalance between intracellular and 
extracellular environments. With restored blood flow, glucose returns to the 
nutrient deficient region, is taken up by glucose receptors returning the cell to 
normal concentrations, but not altering the apoptotic cascade already in motion. 
If verapamil is administered IA, it will stabilize the flow of calcium by blocking the 
L-type calcium channel inhibiting downstream effects by increased intracellular 
calcium. This was demonstrated with preservation of mature neurons in the 
infarct region of the treated group versus the control group. Next we looked at 
astrogliosis which results from dying cells releasing cytokines that attract/activate 
astrocytes to the damaged region. Astrocytes will clean up cellular debris and 
form a "wall" around the infarct helping support those neurons that are still viable. 
Increased astrocyte infiltration/activation is a marker of cell distress. Control 
brains showed a greater number of astrocytes in and surrounding the infarcted 
region compared to treated brains. This correlates with the mature neuron data, 
as greater neuronal death in the infarcted region will lead to increased astrocyte 
infiltration/activation peri-infarct. Using a marker of apoptosis we again looked to 
see if verapamil preserved cells in the infarcted region and found fewer positive 
apoptotic cells in the infarcted region of the treated group than the control. This 
demonstrates with both mature neuron survival and decreased apoptosis that 
verapamil treatment following MCAo and IA administration has a neuroprotective 
benefit on a cellular level.  
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 Verapamil used as an adjunctive therapy following successful 
recanalization in a mouse model of stroke has been demonstrated to be safe, 
have a non-significant effect on blood perfusion, improve functional outcome, 
preserve neuronal health, and decrease astrocyte infiltration, and apoptosis. 
Here verapamil is shown to have neuroprotective benefits, but it is through the 
mechanism of action as an L-type calcium channel blocker that we propose its 
neuroprotective effect and not through vasodilation.  
Combinational Therapy  
 Clinical neuroprotection trials of the past have focused on one drug to 
treat all aspects of stroke (15). Based on current literature we know that a brain 
undergoing a hypoxic event displays a myriad of cellular events (5, 85). The 
expectation of one drug being able to treat multiple pathways is unrealistic, 
where a more practical approach would be to use a combination of drugs to 
target specific cellular pathways. As the brain experiences a stroke, cells 
undergo different stages of degeneration depending on their location in the 
neurovascular unit. Neurons in the core, those that surround and receive 
nutrients from the occluded MCA will begin degradation earlier than those cells in 
the penumbra that receive nutrients via a watershed effect from collateral 
vessels.  
 Utilizing a multi drug approach will allow for broader treatment of cells 
undergoing varying stages of cellular degeneration. Potential neuroprotective 
compounds should be targeted to specific pathways, not have overlapping 
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effects (vasodilation), FDA-approved, and work synergistically. Potential 
neuroprotective compounds were selected based on the above parameters. 
Verapamil and lubeluzole (indirect NMDA antagonist) have both demonstrated 
neuroprotective effects in pre-clinical and clinical stroke models. Verapamil, as 
mentioned above, works acutely through blocking calcium channels on the 
membrane surface helping restore extra/intracellular calcium homeostasis. 
Lubeluzole works in a more delayed fashion and has a proposed mechanism of 
action through inhibiting the release of glutamate, nitric oxide synthase, and Na+ 
and Ca2+ channels (47-50, 86, 87).  
 Testing the synergistic effect of IA combinational therapy following ELVO 
using physiological measures showed a decreased heart rate but a pulse 
distention similar to baseline at 5 and 10 minutes post-drug injection. Compared 
to control, heart rate measurements were not significantly different but pulse 
distention showed a significant increase. Decreased heart rate was seen in both 
groups (control and treated) and could be attributed to anesthesia as is seen in 
baseline measurements. There is no difference between groups 5 and 10 
minutes post-IA administration compared to control, if combinational therapy has 
an effect on heart rate it is negligible from control animals receiving saline. 
Increased pulse distention for the treated group, while significant from the control 
group, demonstrates rescuing effect returning measurements to baseline, 
animals were followed beyond graphed measures and all animals survived the 
surgery with no complications.  
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 Results from combinational therapy versus control using rotor rod and 
open field demonstrated a protective effect for the treated group in both tests. 
Control and treated groups decreased from baseline on PSD 1 and are not 
different and subsequent testing days show the treated group improving 
significantly when compared to control. The positive functional effect seen 
between groups is attributed to preservation of neurons in the motor cortex, 
allowing the mouse to regain forelimb mobility. While rotor rod tests forced motor 
movement and the animals ability to stay on an accelerating rotating rod, open 
field tests both distance covered and health. When a mouse undergoes stroke 
they limit their movement as can been seen on PSD 1, but as the mouse 
recovers they will begin to explore (increase distance covered) the box moving 
from corner to corner. The combinational therapy group significantly improved 
from PSD 1 measurements to PSD 7, while it’s not significant from control PSD 7 
it shows increased exploration and distance covered (two measures of overall 
health). 
 Histological measures were analyzed to determine if combinational 
therapy had a protective cellular effect. Infarct volume analysis demonstrated a 
significant reduction (75%) in the treated group compared to control. This 
extended to both mature neuron survival and astrogliosis in the infarcted region. 
Combinational treatment conferred neuroprotective benefit at PSD 7 both for 
decreased infarct volume, significantly increased mature neurons, and 
significantly decreased astrogliosis. Cellular health in the neurovascular unit 
following stroke is measured by mature neuron survival and astrogliosis. With a 
   
 
118 
 
decreased infarct, the treatment group improved neuronal health leading to a 
decreased need for support and debris clean up from astrocytes. Verapamil is an 
acute therapy blocking L-type calcium channels which are opened once the 
membrane becomes depolarized. Neurons undergoing this stage of apoptosis 
will be found in the penumbral regions, they receive a watershed of blood supply 
and are not directly affected by the MCA. Lubeluzole works in a delayed fashion 
and targets those neurons with a depolarized membrane (past verapamil’s 
mechanism of action) to inhibit glutamate release and NMDA receptor influx of 
calcium. Because of its delayed mechanism of action, lubeluzole will target those 
neurons surrounding the MCA and receiving direct blood supply. These neurons 
will be farther along in cellular degeneration and in the range for targeted 
treatment for lubeluzole.  
 While preservation of neurons is the goal, a secondary measure of brain 
health is astrocyte infiltration/activation. Astrocytes are routinely found throughout 
the brain providing support, but following injury astrocytes migrate towards the 
site of injury and take on roles of cellular debris cleanup and support. Following 
ischemia, additional astrocytes will infiltrate the ischemic region and surrounding 
area to help mitigate the damage, a lower density of astrocytes marks less 
cellular damage. Comparing groups, there are significantly less astrocytes in and 
around the infarcted region for the treatment group. Combined with decreased 
infarct volume and increased mature neuron survival lends credence to 
verapamil and lubeluzole working together in a neuroprotective fashion.  
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     Stroke is associated with a wide variety of symptoms, which are directly 
related to the effected cerebrovasculature and surrounding tissue. When a brain 
undergoes a hypoxic event there is a gradient of cell death, with cells closest to 
the MCA losing nutrients first and start down the apoptotic pathway before those 
receiving nutrients from watershed vessels (penumbra). This leads to neurons 
undergoing various stages of apoptosis, thus the need for a drug(s) that can 
target various stages of cell death. Using a combinational approach, we selected 
one acute acting drug (verapamil) and one delayed (lubeluzole). Both drugs are 
FDA-approved and have shown benefit in pre-clinical and clinical trials. Drug 
synergy is important when combining therapies and care must be taken to 
account for physiological measures during and following drug administration. 
Using an IA model mitigates systemic side-effects commonly associated with 
oral, patch or intravenous drug administration. Heart rate and pulse distention 
measurements show no deleterious effects during IA drug administration.  
 Primary outcomes for many clinical trials are improved functional scores 
90 days post stroke, in a pre-clinical stroke setting animals are tested acutely 
(PSD 1) and long-term (PSD 7+) to determine functional recovery. Intra-arterial 
combinational therapy demonstrated a beneficial motor outcome at PSD 7 for 
both a forced motor and free roam movement. This was correlated to decreased 
cell death in the effected MCA and surrounding territory, simply; brain tissue was 
preserved and had improved function compared to control.  
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 Selecting drugs that target different apoptotic pathways, a broader range 
of cells undergoing various stages of apoptosis can be treated and returned to 
normal function. Presented here are two such drugs that are FDA-approved and 
either underwent or are undergoing clinical trials. Whether they are the drugs that 
will help future stroke patients regain normal function or simply demonstrate drug 
synergy it is a step in the right direction. 
Summary 
 Stroke remains a leading cause of mortality and morbidity worldwide. Here 
we focus on a subset of ischemic stroke, ELVO, and a novel method of delivering 
potential neuroprotective compounds. Drugs were selected based on pre-clinical 
and clinical testing, FDA-approval, and drug compatability. Studies have shown 
that GTN, verapamil, and verapamil and lubeluzole conferred a neuroprotective 
benefit. Each drug tested worked through a specific pathway either acutely or in 
a delayed fashion. Combining potential therapies requires drugs having 
independent mechanisms of action targeting a variety of cellular processes. Here 
we present a stepping stone for future researchers to expand upon our work and 
eventually develop a therapeutic for the treatment of stroke. 
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